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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder
and the most common form of dementia. Considering the aging population,
AD will be one of the challenging problems of the public health in the near
future.  Current  medication  used  for  AD  can  only  alleviate  the  symptoms
temporarily;  therefore it  is  imperative to identify new therapeutic targets to
prevent the progression of the disease. Being one of the early key events in
early AD pathology, chronic inflammation precedes the cognitive decline and
an increasing interest has been focused on identifying potential targets within
inflammatory cascades. 
Macrophage  Migration  Inhibitory  Factor  (MIF)  is  a  multi-potent  pro-
inflammatory  cytokine,  which  promotes  production  of  other  proinflammtory
mediators.  MIF  is  synthesized  by  several  cell  types  in  the  brain  such  as
microglia,  astrocytes  and  hippocampal  neurons,  and  is  secreted  in  early
asymptomatic stage of the disease, which might contribute to the persistent
activation of glial cells and perpetuating neuroinflammatory responses leading
to neurodegeneration. In this project we hypothesized that inhibition of MIF
can attenuate the inflammatory milieu in the brain and improve the cognitive
deficits as a result of chronic cytokine production.
We used Intracerebroventricular Streptozotocin Injections (STZ-ICV) to test
our hypothesis.
In in vitro experiments, ISO-1 was used to inhibit the MIF molecule in primary
astrocyte,  neuron and microglia treated with proper concentrations of  STZ
molecule as stimulus. The cytokine response was documented in protein and
mRNA level.  The  collected  in  vitro data  suggests  that  MIF  inhibition  can
alleviate  inflammation  by  down-regulating  production  of  proinflammtory
cytokines (such as IL-6 and IL-12p40).
In vitro  experiments were followed up by in vivo behavioral assessment of
cognitive deficits and cytokine production in streptozotocin induced model of
neurodegeneration.  For  this  purpose,  MIF-KO  and  wild  type  mice  were
intracerebroventricularly  injected  with  streptozotocin  (STZ-ICV)  or  vehicle
(Veh-ICV). 
We confirmed that by triggering an ongoing and chronic immune response,
STZ interferes  with  learning via  disrupting the spatial  learning in  C57BL/6
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mice. 
We  observed  significant  relationships  between  cognitive  improvement  (in
terms  of  contextual  memory)  and  MIF  inhibition  in  STZ-ICV  model  for
neuroinflammation.  The  inhibition  of  MIF  (by  novel  Intraperitoneal  (IP)
application of ISO-1), tended to improve the spatial learning and memory in
the context of clockmaze and fear conditioning in wild type animal.
Similar trend as  in vitro  has been observed in down regulation of cytokines
(IL-6 and IL-12p40) as a result of MIF inhibition.
In contrast to wild type STZ-ICV, we observed no significant upregulation in
inflammatory  mediator  or  glial  cell  markers  in  mRNA levels  of  MIF-KO
animals.
In  conclusion,  the  results  from my thesis  confirms the  role  of  MIF  as  an
upstream cytokine in regulating secretion of other inflammatory mediators and
shows  the  potential  of  this  molecule  as  a  therapeutic  target  to  attenuate
cytokine induced cognitive deficits.
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1. Introduction
Several  neurodegenerative  disorders,  such  as  Alzheimer’s  disease
(AD) and Parkinson’s disease (PD), share common features that lead to a
loss of function followed by neuronal death within the central nervous system
(CNS).  Remarkably,  researchers  have  identified  familial  forms  of  these
neurodegenerative disorders that are strongly linked to rare genetic mutations
that,  invariably,  produce  an early  onset  and faster  course of  the  disease.
However, the more common and sporadic forms of neurodegeneration occur
as  a  result  of  a  combination  of  factors,  such  as  protein  misfolding  and
oxidative stress. It is somewhat surprising that until recently these causative
factors have been less studied than the genetic mutations.
Brain inflammation, or neuroinflammation, has emerged as a critical factor to
consider  when studying the origin of  neurodegenerative  disorders.  In  fact,
several  findings  indicate  that  the  activation  of  glial  cells  and  ongoing
neuroinflammation  in  the  CNS  may  play  a  central  role  in  many
neurodegenerative  diseases,  such  as  AD  and  PD.  The  exaggerated
inflammatory responses to immune stimulation in the brain have been shown
to lead to impaired microglial and astrocyte function. It is also believed that
disease progression,  particularly  at  the  pre-neurodegenerative  stages,  can
result  in  behavioral  deficits,  such  as  cognitive  impairments.  Furthermore,
when  patients  use  anti-inflammatory  drugs,  such  as  nonsteroidal  anti-
inflammatory drugs (NSAIDs), they appear to be at lower risk of developing
neurodegenerative diseases.
1.1. Glia in the central nervous system
Proper brain function depends on the precise interaction of different
types of the cells in the CNS, especially neurons and glia (Kolodziejczyk et al.
2010). Glial cells can alter their shape and function in response to internal
and  external  signals  to  serve  different  purposes  in  the  CNS,  such  as
regulating  the  formation  of  brain  regions  during  early  brain  development.
These cells also play a key part in the proper  functioning of the adult CNS
and are crucial for supplying the neurons with the appropriate nutrients and
signals (Fields, Stevens-Graham 2002). For instance, myelinated axons in the
CNS  are  en-sheathed  by  oligodendrocytes,  which  support  the  axon  and
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modulate  signal  transmission  (Russell,  1990).  It  is  clear  that  neurons  are
highly dependent on glial cells, which support them by supplying nutrients, by
modulating the synaptic communication between neurons, and by providing
homeostatic factors that are crucial for the well-being of neurons. Another key
aspect  is  that  glial  cells  are  responsible  for  the  clearance  of  extracellular
molecules (Araque, Navarrete 2010). In recent years, it has become apparent
that  yet  another  key  role  for  glial  cells  is  the  regulation  of  inflammatory
response in the brain (Czeh et al. 2011).
1.1.1. Oligodendrocytes: 
Oligodendrocytes are the myelin producing cells within the CNS, which are
differentiated directly  from progenitor  cells.  Myelin  is  produced as a spiral
structure from extensions of the plasma membrane (Simons, Nave 2016), and
it functions as a physical barrier for protecting the axons of neurons and for
increasing the speed of  the axonal  conductance (Kandel  2000).  Nodes of
Ranvier  are  the  spacers  along  a  myelinated  axon,  wherein  the  axon  is
exposed to the extracellular environment (Baumann and Pham-Dinh, 2001).
Demyelinating diseases such as multiple sclerosis manifest  as acute focal
demyelination and loss of axons. Other resident cells of the CNS such as
astrocytes and microglia express modulatory factors, which affect the course
of  neurodegenerative  diseases  by  influencing  the  maturation  of  the
oligodendrocytes.
1.1.2. Microglia: 
These cells  comprise up to 12% of  the cells  in  the murine CNS (Dri  and
Gordon, 1990). They are considered the macrophage-like resident cells in the
CNS because they control innate immunity regulation, which they attain by
monitoring  the local  brain  environment  for  any  sign  of  pathogen  intrusion
(Kandel 2000). Interestingly, the developmental origin of microglia is recently
been delineated with the use if genetic mapping techniques. It is clear that
primitive macrophages from the yolk sac, a group of progenitor cells, migrate
from  the  mesoderm  into  the  neuroectoderm  early  in  development  and
differentiate into immature microglia (Chan et al. 2007), which then migrate to
CNS areas named fountains  of  microglia  and proliferate into  mature cells
(Mouton  et  al.  2002). Resting  microglia  play  a  key  role  in  supporting  the
neurons and clearing extracellular debris (van Rossum, Hanisch 2004), as
they also constantly sample their local area for danger signals (Raivich 2005).
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Also during brain development, microglia are necessary for neural refinement.
The overall number of microglia seems to be constant in the brain. Tissue
injury leads to their proliferation, but this is normally followed by apoptosis,
which controls the total number of these cells (Gehrmann, Banati 1995). The
density of microglia differs in distinct brain regions; the highest numbers are
found  in  the  hippocampus,  basal  ganglia,  and  substantia  nigra,  while  the
numbers are low in fiber tracts, the cerebellum, and brain stem, (Block et al.
2007). In addition,  the size of microglia varies in relation to different  brain
regions; in fiber tracts, they are highly branched and occupy a territory with a
cross-section of ~200 m2, whereas hippocampal microglia occupy a territory
of ~550 m2 and are far less branched (Lawson et al. 1990).The activation of
microglia  leads  to  morphological  changes,  secretion  of  cytokines,
phagocytosis,  and  presentation  of  antigens  (Garden  &  Moller,  2006).
Importantly,  microglia  return  to  their  resting  state  once  the  problem  is
resolved. MHCII, CD86, CD68, scavenger receptors, and integrins are used
as markers of microglial reactivity. Activation of microglial cells upstream of
CNS inflammatory responses is necessary for cytokine production by other
glial  cells and is also a critical  step in inflammation-mediated neurotoxicity
(Block  et  al.  2007).  Recent  findings  show that  the  older  classification  of
microglia into M1 (pro-inflammatory) vs. M2 (anti-inflammatory) appears too
simplistic, because these cells are involved in a wider range of processes,
including neurodegeneration and synaptic function. The latter,  for example,
can be regulated indirectly by microglia that engulf synapses and through the
production  of  chemokine  and  cytokines  modulate  neuronal  synapses
(Parkhurst et al. 2013).
Postmortem studies of brains from AD patients have shown that amyloid and
tangle pathologies correlate with the expression of specific microglial markers
that  control  the  activation  of  microglia,  particularly  neuroimmunoregulatory
proteins (NIRegs), which are listed in Table 1. NIRegs are a group of proteins
expressed  in  different  brain  cells  that  act  on  microglia  through  specific
interacting  receptors  (Table  1).  Notably,  each  NIReg  may  represent  a
potential therapeutic target for controlling the progression of inflammation. 
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NIRegs Interacting receptors
CD200 CD200R
CD22 CD45
CD74 SIRPα
semaphorin Plexin B1/CD72
fractalkine Fractalkine receptor
Table 1: Neuroimmunoregulatory proteins (NIRegs) acting on microglia 
Microglia  are  “primed”  as  a  result  of  aging.  The  primed  cells  show  a
prolonged and amplified inflammatory response to stimulation, which might
lead  to  exaggerated neuroinflammation and  potentially  long-term cognitive
deficit. Priming can occur as a result of normal aging in humans and other
mammals,  such as mice and rats  (Streit,  Sparks 1997). Microglial  priming
also leads to increased oxidative stress  (Godbout et al. 2005). Markers that
are used generally for activated microglia cannot be used in the context of
microglial reactivity with aging. Although increased oxidative stress is thought
to  play  the  dominant  role  in  age-related  priming,  the  presence  of  certain
proteins  (or  DNA)  is  also  considered  a  causative  factor  in  aging  (Sohal,
Weindruch 1996). In rodents, aging is accompanied by increased glial activity,
increased scavenger receptors  (Godbout et al.  2005) as well  as increased
MHC II expression in microglia (Frank et al. 2006).
1.1.3. Astrocytes: 
 Astrocytes are the most abundant glial cells in the CNS (80% of all  glia).
These  star  shaped  cells  participate  in  many  functions  that  ensure  the
homeostasis  of  brain  neurons,  such  as  providing  nutrients  and  being
associated  with  synapses  and  axonal  terminals,  in  which  they  clear  the
excess of neurotransmitters and potassium ions after the occurrence of action
potentials (Kandel 2000). Astrocytes are part of the blood brain barrier (BBB)
and play a  highly  specialized role  in  innate immunity  by cooperating  with
microglia. It is also increasingly clear that astrocytes are involved in a variety
of CNS neurodegenerative disorders (Watkins et al. 2008), such as AD and
PD (Sofroniew, Vinters 2010).  Depending on their morphology and location,
astrocytes  can  have  different  functions  and  can  be  classified  into
protoplasmic  (type  I)  and  fibrillary  (type  II)  groups  (Bond  et  al.  2006).
Importantly, these two classes of astrocytes differ in their electrical properties
(Table. 2).
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Type I Type II
Main location gray matter white matter
Input resistance low high
Potassium currents voltage and time-independent
voltage-
dependent
uptake + low
Membrane potential Extremely negative negative
Recognition Marker GFAP S100b
Morphology Extremely branched tripartite
Table 2: different type of astrocytes
Protoplasmic (type I)  astrocytes  constitute the vast  majority of  glial
cells,  and  show  irregular  morphology  and  dense  branching.  These  cells
normally populate the grey matter and areas around blood vessels, with their
processes  surrounding  synapses  and  neuronal  cell  bodies  (Volterra,
Meldolesi 2005). Type I astrocytes are immunoreactive for GFAP, a marker
that  is  widely  used  to  label  them  in  brain  samples,  especially  in  the
hippocampus,  cerebellum  and  cortex.  Interestingly,  GFAP  is  upregulated
following  inflammation  (Farina  et  al.  2007) and during  neurodegenerative
diseases  (Thal et al. 1999).  GFAP is also strongly expressed in neurogenic
areas of the hippocampus.
Fibrillary (type II) astrocytes express the calcium binding protein S100, have
a simple morphology, and are found in white matter in cooperation with nodes
of Ranvier. This population of astrocytes is much less immunoreactive than
type I astrocytes. Other markers expressed on the membrane of astrocytes
include  Glt-1  and  GLAST,  which  are  markers  for  glutamate  transporters.
Given that Glt-1 and S100 are also expressed in oligodendrocytes, they are
not considered exclusive astrocytic markers (Nishiyama et al. 1999).
Additionally, Bergmann glial cells are a separate category of astrocytes, which
are present only in the cerebellum where they modulate the function of local
neurons  (Hirrlinger  et  al.  2004).  Apart from  glial  cells,  perivascular
macrophages are located near the vascular endothelia, whereas meningeal
macrophages are found at the basement membrane surrounding the blood
vessels and in the subarachnoid space (Kennedy, Abkowitz 1997).
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These  two  types  of  brain-residing  macrophages  function  similarly  to
peripheral  macrophages.  These  cells  express  CD45  receptor  at  a  much
higher level in comparison to microglia cells.
1.2. Cross-talk between astrocytes and microglia
The  communication  between  astrocytes  and  microglia  plays  an
important role in the pathology of the inflammatory response. It is also clear
that  astrocytes  and  microglia  are  activated  at  different  stages  of  the
neurodegenerative diseases (Jebelli et al. 2014). In general, the activation of
astrocytes is subsequent to local microglial activation, but it  then facilitates
and amplifies the immune response by  microglia  (Lokensgard et al. 2016).
This leads to the production of different substances, such as growth factors
that can promote microglial growth and activation and modulate its cytotoxic
activity  (Loane,  Byrnes  2010).  Cytosolic  calcium  increases  as  a  result  of
astrocyte activation, and it controls the release of excitatory neurotransmitter
and extracellular glutamate (Fellin, Carmignoto 2004).
Astrocytes  decrease  the  production  of  microglial  NO,  ROS  and  tumor-
necrosis-factor-TNF,  and  inhibit  the  expression  of  co-stimulatory
molecules responsible for  the stimulation of  dendritic  cells (Acevedo et  al.
2013).  These  cells  can  also  suppress  the  phagocytic  activity  of  microglia
through  the  production  of  transforming  growth  factor  β  (TGF-β),  thus
hindering the efficient clearance of senile plaques (DeWitt et al. 2008).
1.3. Neuroinflammation
Inflammation is an active process that occurs in response to danger
signals,  with  the purpose of  removing or  inactivating  potentially  damaging
agents  or  damaged  tissue.  The  brain  is  almost  isolated  from  systemic
circulation by the BBB, and therefore the inflammatory signals are primarily
resolved  by  brain-residing  microglia.  These  cells  are  responsible  for
monitoring the micro-environment to sense injury or pathogen invasion. When
such stimuli are detected, microglia become activated and release a cocktail
of inflammatory mediators (cytokines, chemokines, etc.), which interact with
neighboring astrocytes and neurons (Glass et al. 2010) and indicate the onset
of  the  local  inflammatory  response  (Gonzalez-Scarano,  Baltuch  1999).
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Indeed,  local  inflammation is  initiated by an interaction  between pathogen
associated molecular patterns (PAMPs), present in the pathogenic organism,
and  pattern  recognition  receptors  (PRRs)  located  on  the  membrane  or
intracellularly  in  microglial  cells.  NOD-like-receptors,  RIG-1-like-receptors,
Toll-like-receptors (TLRs), and C-type-lectin-receptors are four PRRs that are
involved in these interactions  (Takeuchi, Akira 2010). Up to twelve different
types of TLRs have been characterized in murine and human cells. These
membrane  molecules,  which  are  widely  expressed  on  astrocytes  and
microglia, are rarely expressed on neurons (Konat et al. 2006). Signaling via
PRRs  can  activate  downstream  signaling  pathways,  such  as  IB  and
mitogen-activated  protein  kinase  (MAPK),  leading  to  the  activation  of
transcription  factors  such  as  nuclear  factor  B  (NF-B)  and  interferon
regulatory factors (Smale et al., 2010). Eventually, this leads to the release of
pro-inflammatory  cytokines  such  as  TNF-,  interleukin- (IL-1),  and
interleukin-6  (IL-6)  to  enhance  the  response.  The  microglia-released
mediators  can  also  engage  systemic  immune  cells  to  facilitate  the
inflammatory processes (Glass et al. 2010).Since the brain is very sensitive to
tissue damage,  several  counter-regulating  mechanisms are used to tightly
regulate  and  terminate  the  inflammation within  the CNS.  For  instance,up-
regulation of anti-inflammatory mediators such as IL-10 counter-regulates the
cytokine production from microglia and astrocytes.
1.4. Inflammation and neurodegenerative diseases
An increasing body of evidence indicates that inflammatory processes
are  involved  in  the  pathophysiology of  many neurodegenerative  diseases,
such as AD, PD, amyotrophic lateral sclerosis (ALS) and multiple sclerosis
(MS). All  of  these disorders can be characterized by massive activation of
microglia and astrocytes (Glass et al. 2010), leading to prolonged secretion of
inflammatory  mediators  including  chemokines,  cytokines  and  complement
factors.  Activated  microglia  release  pro-inflammatory  cytokines,  such  as
interleukin-1 (IL-1), IL-6, and TNF-α (Rivest 2009).
The innate immune response results in local inflammation, which is critical for
eliminating  the  invasive  elements  but  also  for  causing  detrimental  tissue
damage as a bystander injury (Rivest et al., 2009). When local inflammation
is not resolved in a timely fashion, it leads to the activation of distal microglia
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because they also react to pro-inflammatory cytokines, and this seems to be
a critical event for propagating the inflammation (Rosenberg et al. 2006). In
fact, histological studies have shown that early, focal activation of glial cells
can  lead  to  a  global  increase  in  the  expression  of  IL-1,  IL-6,  and  up-
regulated activity of BACE1 (Heras-Sandoval et al. 2016). Also, the release of
pro-inflammatory  cytokines  lead  to  the  inhibition  of  hippocampal
neurogenesis,  as  well  as  neuronal  dysfunction  or  death  by  a  variety  of
mechanisms,  including  enhancement  of  glutamate-induced  excitotoxicity
(Marambaud  et  al.  2009).  Interestingly,  high  serum  levels  of  systemic
inflammation markers can be used to predict cognitive decline or dementia in
subjects  with  normal  cognition  (Trollor  et  al.  2012),  indicating  that
inflammatory processes precede mild cognitive impairment (MCI) in patients
(Albert et al. 2011). 
1.4.1. Cytokines: 
Cytokines are humoral proteins with low molecular weight and various
activities  depending  on  their  target  cells.  These  immune  response-related
molecules  and their  receptors are expressed in  all  CNS cell  types  (Allan,
Rothwell 2001). The levels of multiple pro- and anti-inflammatory cytokines
are elevated in the CNS in response to pathological stimuli. TNF- and IL-
1are quickly upregulated in cells as the first wave of cytokines, in response
to insults (Dinarello et al. 2000). This is followed by expression of the second
wave  of  inflammatory  mediators,  including  IL-6  and  chemokines,  such  as
CXC  and  fractalkine  (Geisterfer  et  al.  1995).  Aging  can  also  lead  to  the
progressive increase in expression of certain cytokines such as interleukin
(IL)-1  and  IL-6  (Godbout,  Johnson  2004).  In  rat  models,  aging  leads  to
dramatic increase in  TNF-α  gene expression (Gemma et al.  2002). In AD-
affected brains, both complement factors and cytokines are upregulated in
damaged  neurons  (Akiyama  et  al.  2000).  Primarily,  this  upregulation  is
supposed to remove the detritus from pathological processes, however over
time it  causes damages to CNS. This effect can be partially inhibited after
administration of non-steroid anti-inflammatory drugs to AD patients (Etminan
et  al.  2003),  indicating  the  injurious  effect  of  chronic  increase  of  the
inflammatory mediators over an extended period of time.
Expression  of  pro-inflammatory  cytokines  is  inhibited  by  many  feedback
mechanisms,  many  of  which  include  upregulation  of  anti-inflammatory
mediators such as IL-10. However a concomitant increase of these proteins is
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missing in neurodegenerative conditions, implying that the balance between
pro-  and  anti-inflammatory  members  of  the  innate  immunity  is  disrupted.
Interestingly,  chronic  inflammation  leads  to  ongoing  expression  of  the  pro
inflammatory cytokines (Caraci et al. 2011), meanwhile it results in decrease
of  hippocampal  neurogenesis  and  down  regulation  of  anti-inflammatory
cytokines (Butters et al. 2008). Of interest in this thesis is the involvement of
inflammatory cytokines in chronic inflammation. Specificly, we investigate MIF
release as a result of streptozotocin (STZ) stimulation from astrocytes and
microglia,  and  determine  the  degree  by  which  STZ-induced
neuroinflammatory  cytokines  are  released.  The  rationale  behind  choosing
STZ for in vitro experiments will be discussed in details in the next section. To
explain  it  briefly,  after  ICV injection  of  this  molecule  in  the  hippocampus,
numerous inflammatory mediators including cytokines, chemokines and nitric
oxide  are  released  from glial  cells.  STZ induced  changes  lead  to  a  self-
propelled  and  maintained  inflammation  in  the  CNS  even  6  weeks  after
surgery, which is similar to the “hit and run phenomenon” explained by Nath
and colleagues in 1999. The cytokine upregulation is followed by behavioral
changes including cognitive deficits in the animals, which makes this model
proper for the investigation of neuroinflammation driven cognitive deficits and
dementia.
The role of some key cytokines in neurodegenerative diseases is described in
the following section.
1.4.1.1. IL-1beta: 
IL-1  is one of the cytokines involved in inflammatory response in the
brain  (Shaftel  et  al.  2008).  This  cytokine  is  constitutively  produced  by
neuronal and glial cells (Veerhuis et al. 1999) and is released in response to
activation  of  innate  immunity.  This  cytokine  resembles  many  neurotoxic
characteristics  of  TNF-  (Yadav,  Collman  2009);  both  molecules  play  a
determining role in inducing neuronal death in chronic inflammation (Brabers,
Nottet,  2006).  Although the mRNA expression of  IL-1 remains unchanged
(Sheng  et  al.  2001,  Zhao  et  al.  2001a)  upon  stimulation,  the  inactive
precursor form is cleaved (which activity is increased by normal aging) by
caspase-1 to generate the active form of the  enzyme (Gemma et al. 2005),
which binds with high affinity to its receptor, IL-1RI (Dinarello 1998). IL-1RI is
highly  expressed  in  certain  areas  of  the  brain  such  as  the  hippocampus
(Friedman 2001).
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IL-1 expression in CNS derives mostly from activated microglia (Zhao et al.
2001b), and it regulates the proliferation of cells by activating the NF-κB/Iκκ
pathway  (Koo,  Duman,  2008).  It  directly  affects  the  survival  of  newborn
neurons  by  inducing  apoptosis  via  phosphorylation  of  the  stress-activated
protein  kinase/Jun-amino-terminal  kinase  (SAPK/JNK)  pathway  in  vitro
(Zhang et al. 2013). This mediator increases the differentiation of astrocytes,
which can be determined by measuring GFAP marker (Wang et al.  2007),
resulting in subsequent production of TNF-  and iNOS (Zhao et al. 2001a,
Jana et al. 2005). 
1.4.1.2. IL-6:
IL-6  is  a  multifunctional  cytokine secreted upon stimulation,  and is
produced by a variety of cells within the CNS, such as astrocytes, microglia
and neurons (Erta et al. 2012). The expression of this protein is extremely
altered by aging as a result of age-related changes in the normal regulation of
the cytokine, thus this protein is referred to as “a cytokine for gerontologist”
(Daynes et al. 1993). IL-6 is elevated in association with senile plaques and
neurofibrillary tangles in the AD (Wang et al. 2015), and is also elevated in the
blood of the patients with cognitive decline, post-operative delirium (Capri M.
et al. 2014). 
IL-6 is produced in the second wave of cytokines in response to a stimulus,
and  it  induces  the  synthesis  of  other  inflammatory  substances,  including
acute phase proteins (Gabay C, Kushner 1999). It is a key regulatory for the
acute  phase  of  inflammation;  at  this  stage  IL-6  can  also  exert  anti-
inflammatory properties that counteract the induced pathology by TNF-, by
triggering the production of IL-10 (Tilg et al. 1994). In animal studies IL-6 is
shown  to  both  inhibit  and  promote  neurodegeneration  depending  on  the
context (Allan et al. 2001). Increased plasma levels of IL-6 are a marker for
the cognitive decline in elderly (M.T. Heneka et al. 2014)
1.4.1.3. TNF-α:
TNF- is  a  pro-inflammatory  cytokine  involved  in  many
neurodegenerative  diseases,  for  instance  AD,  PD,  stroke  and  multiple
sclerosis. This cytokine is a type II transmembrane protein. The active form is
26  kDA  homo-trimer,  which  is  processed  by  TNF- converting  enzyme
(TACE/ADAM17) to a 17 kDa active protein. Two different trans-membrane
receptors  exist  for  this  cytokine:  TNF  receptor  type  I  (TNFR1),  which  is
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expressed on different cells, and TNF receptor type II (TNFR2) expressed on
immune cells in low levels  (Dembic et al.  1990,  Cabal-Hierro, Lazo 2012).
Stimulating TNFR1 leads to activation of apoptotic pathways (Beyaert, R et al.
1995),  whereas TNFR2-mediated signaling  pathway provokes  cell  survival
and proliferation (Okamoto et al. 2009), it also can activate NF-kβ via PI3K-
PKB/Akt  signaling  pathway  (Marchetti  et  al.  2004).  A  balance  between
activation of these two receptors, plays a pivotal role in determining whether
TNF- acts  in  a  neuroprotective  or  neurodegenerative  way.  As  mentioned
before, neuroinflammation has been shown to play a significant role in the
progression of neurodegenerative diseases.  TNF- is  one of the important
mediators released by glial  cells  in  this  process  (McAlpine,  Tansey 2008).
High TNF- levels promote progressive pro-inflammatory processes, which
later may contribute to degeneration of neurons in the brain (Melinda E Lull.
et al. 2010). Multiple polymorphisms in the TNF-α gene are associated with
higher risk of developing AD (Di Bona et al. 2009). This is also confirmed by
the observation that higher levels of TNF- are detected in AD brain tissues,
which is thought to have a microglial source (Benzing et al. 1999, Zhao et al.
2003). TNF- and its receptors contribute to neurodegenerative conditions in
murine models as well. It has been shown that TNFR1 signaling exacerbates
cognitive decline in a mouse model of traumatic brain injury (TBI-Longhi et al.
2013), whereas activation of TNFR2 attenuates it. Targeting these molecules
and the signaling pathways they initiate, can contribute to the development of
potential therapeutic strategies.
1.4.1.4. IL-12: 
Members of IL-1.2 family play a critical role in the innate and adaptive
arms of the immune system. IL-12 is one of the cytokines increased during
early and acute infections (Nilsson et al. 2007), whereas the levels for this
cytokine are normally reduced in chronic infections, such as HIV (Marshall et
al., 1999). This cytokine controls the secretion of IFNγ by Th1 cells (Trinchieri
2007), and it inhibits Th2-dependant IL-10 production (Marshall et al. 1999).
The active form of IL-12 is a heterodimer, composed of two subunits, p35 and
p40. It exerts its activity through interacting with IL-12 cell surface receptors
and promotes the polarization of the CD4+ T cells to Th1 phenotype (Takuma
Kato et al. 2000, Hoshino et al. 2013). IL-12 receptor consists of two subunits,
IL-12Rg1 and g2 (Chua et al. 1995, Presky et al. 1996).
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1.4.1.5. IL-10: 
Whereas  most  pro-inflammatory  cytokines  are  accepted  as
predominantly neurodegenerative, anti-inflammatory mediators are viewed as
rather  neuro-protective  (Ross  et  al.  2003).  Under normal  conditions  anti-
inflammatory cytokines are released in order to regulate the expression of the
pro-inflammatory  cytokines  (Hurley,  Tizabi  2013).  Being  one  of  the  best
known  anti-inflammatory  mediator,  IL-10  expression  is  upregulated  in
activated microglia (Koscso et al. 2012). This upregulation is thought to inhibit
the  transcription  factor  NF-κB,  thus  resulting  in  prevention  of  antigen
presentation on immune cells. This is followed by attenuated expression of IL-
6. Also, expression of IL-1, TNF- and chemokines are downregulated by IL-
10,  which  is  followed  by  reduced  antigen  presenting  in  brain  monocytes
(Konsman  et  al.  2002).  IL-10  can  inhibit  the  aggressive  Th1  response
(Leonard, Myint, 2006). Also, when injected intravenously, IL-10 inhibits the
production of TNF- in the brain (Di Santo et al. 1997). Recombinant IL-10
also improves neurological recovery in hippocampus and cortex  (Knoblach,
Faden 1998).
1.5. Macrophage Migration Inhibitory Factor (MIF)
Although macrophage migration  inhibitory factor  (MIF)  was the first
cytokine to be discovered (Bloom and Bennett 1966), it was not well studied
until  its  human  cDNA was  cloned  in  1989  (Weiser  et  al.  1989).  MIF  is
secreted  in  response  to  LPS by  various  cell  types,  such  as  lymphocytes
(Bacher  et  al.  1996),  neutrophils  (Daryadel  et  al.  2006),  and  eosinophils
(Rossi et al.  1998). In contrast to most pro-inflammatory cytokines, MIF is
stored as a preformed mediator that is packed into vesicles (Nishino et al.
1995).  Since  the  structure  of  MIF  does  not  include  a  N-terminal  signal
sequence, it is not translocated into the endoplasmic reticulum (ER), which
would be otherwise necessary for a classical pathway of secretion (Flieger et
al. 2003). Secretion occurs with the use of ATP-binding cassette transporters
(ABCA1) (Flieger et al. 2003). 
The MIF gene consists of 2 introns and 3 exons (205bp, 173bp and 183bp,
Weiser  et  al.,  1989),  and  contains  several  DNA-binding  sequences  for
transcription factors such as AP-1, NF-B, GATA and cyclic adenosine 3’,5’-
monophosphate (cAMP)-responsive element binding (CREB) protein (Roger
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et  al.  2003).  There  is  an  89%  sequence  homology  between  human  and
murine MIF gene sequences (Donn et al. 2004). , In humans, it is located on
chromosome 22q11.2  (Fig.  1-1;  Budarf  et  al.  1997),  which encodes for  a
nonglycosylated 12.5 kDa protein of 115-amino acids. The promoter region of
the MIF gene contains two functional polymorphisms (see Fig.1-1. Bottom).
Figure 1.1.. Structure of the MIF gene:
TOP:  Schematic representation of the human MIF gene. Several consensus DNA-
binding  sequences  for  transcription  factors  are  present  at  5'  regulatory  region
followed by exons one to three are shown as blue boxes (respectively 107, 172 and
66 base pairs). 
Bottom: Cytogenetic location 22q11.23, which is the long (q) arm of chromosome 22
at  position  11.23.  Molecular  location:  base  pairs  23,894,378  to  23,895,222  on
chromosome  22  (Homo  sapiens,  Annotation  Release  107,  GRCh38.p2).  Credit:
Genome  Decoration  Page/NCBI,  Transcription  factor  ICBP90  regulates  the  MIF
promoter  and  immune  susceptibility  locus,  Jie  Yao,  Patty  Lee,  Richard  Bucala
Published February 1, 2016
The MIF protein forms a homo-trimer barrel structure with a channel at its
center (Sugimuto et al. 1996). Each monomer consists of six -strands and 2
anti-parallel  -helices. Both the monomer and trimer forms can exert activity
depending upon the concentration of the protein (Mischke et al. 1998). Figure
1-2 represents the crystal structure of the MIF molecule. MIF exists in two
different trimeric states; the ratio in their mixture is modulated by the binding
of small molecules to the active site of the MIF.
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D-dopachrome  tautomerase  (D-DT),  referred  to  as  MIF-2,  is  the  other
member of the MIF super family, which functions as a homolog to MIF and
shares a similar  protein structure.  The  D-DT gene,  like MIF,  is  located on
chromosome 22 (Merk M. et al. 2012). MIF also shares a similarity in protein
structure  and  functional  activity  with  human  D-DT  and  some  prokaryotic
enzymes (e.g. the 4- oxalocrotonate tautomerase).
1.5.1. Mechanisms of action of MIF: 
The MIF protein can function as an enzyme, cytokine, chemokine and
also a hormone. 
As an enzyme, MIF possesses two enzymatic activities,by either acting as a
tautomerase or as an oxidoreductase. However, the exact physiological role
of  the  enzymatic  activity  of  this  molecule  is  still  being  elucidated.  MIF’s
enzymatic activities are listed in Table 3.
Figure 1.2.: Crystal structure of MIF protein molecule
 Left: Ribbon diagram of  MIF molecules,  composed of  three identical  subunits
(colored in green, purple and brown) each of which contains a four-stranded beta-
sheets with two anti parallel alpha helices.
 Right: the MIF trimmer, the same orientation as in presented in the left picture.
Credit: Giardia lamblia. Buchko GW, Abendroth J, Robinson H, Zhang Y, Hewitt
SN,  Edwards  TE,  Van  Voorhis  WC,  and  Myler  PJ.  J  Struct.  Funct.  Genomics
(2013) 14:47-57. 
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Enzymatic
activity
Dependence Catalytic activity
Tautomerase
activity
Proline-
Proline
Catalyzes  D-dopachrome  or  L-
dopachrome  to  its  indole
derivatives,  Mediated  by  proline
residue present at the N terminal
Thiol-Protein
oxidoreductase
activity
CALC
dependent
Catalyzes reduction of insulin and
HED by GSH and DHL 
Table 3: Enzymatic activities of MIF 
(based on Rosengren and Bucala, 1996; Rosengren and Bucala 1997; Lubetsky and
Swope, 1999)
As a pro-inflammatory cytokine, MIF serves as a mediator to maintain the
inflammatory  response.  For  example,  exogenous  MIF  can  up-regulate  p-
selectin  expression,  which  results  in  TNF-  induced  leukocyte  rolling  and
adhesion  (Simons  et  al.  2011).  MIF  also  functions  by  activating  MAPK,
leading to the secretion of other cytokines and chemokines such as IL-6 and
TNF  (Lue et al. 2006). In cell cultures, it can directly induce TNF-  secretion 
from monocytes  and  macrophages  (Dios  A et  al.  2002).  MIF  induces  the
proliferation of T lymphocytes (Bernhagen et al. 1998). It binds directly to tow
cysteines in p35 (Cys242 and Cys238); this association leads to inhibition of
p35  and  consequently  suppresses  apoptosis.  MIF  acts  as  a  mediator  for
hypothalamic-pituitary-adrenal (HPA) axis in rats (Bay Richter C. et al. 2015)
as  it  is  released from hypothalamus,  pituitary  gland and adrenal  gland in
response to stressful stimuli (Bacher et al. 1998). However, the baseline level
of this cytokine (0.1–100 ng/ml) in healthy serum is much higher than other
cytokines.  MIF  levels  can  rise  as  a  response  to  hormones  such  as
adrenocorticoid hormone (ACTH) (Nishino et al. 1995).
In human studies, MIF is secreted in a diurnal rhythm, with a plasma
concentration  of  0.1-100  ng/ml,  which  can  override  the  hydrocortisone
induced-inhibition of NF-κB activation (Daun et al. 2000). Regardless of MIF
levels being released in hormone-like manner, it apparently functions either
through  catalytic  activity  or  as  a  cytokine.  It  is  also  involved  in  cellular
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migration. MIF-induced CCL2 and MAPK activation has been shown in vitro
to increase migration of mouse neutrophils and macrophages (Edwards KM.
et  al.  2011).  MIF-KO  mice  show  reduced  leukocyte  endothelial  cell
interactions.
Classical  chemokines  including  CXCL8  are  directly  induced  by  MIF.
Additionally, MIF itself has “chemokine-like function” (CLF) that places it in a
similar  group  as  thioredoxin  (TRX)  and  complement  factor  5a  (C5a)
(Bernhagen  et  al.  2007,  Gregory et  al.  2006).  MIF  exerts  its  chemotactic
properties on neutrophils, monocytes and T-cells by binding to cell receptors
CD74/CXCR2/CXCR4 (Bernhagen et  al.  2007).  Other catalytic activities of
MIF include functioning as phenylpyruvate keto-enol isomerase (Rosengren
et  al.  1996),  D-DT  and  a  thiol-mediated  oxidoreductase.  Moreover,  MIF
possesses a CXXC motif, similar to thiol-mediated oxidoreductase enzymes
such as thioredoxin (TRX), which catalyzes the antioxidant activity of these
molecules. This can be observed in the plasma of sepsis patients, in which
there is  a positive correlation between the anti-oxidant  TRX and MIF.  The
amino-terminal proline (Pro-1) residue has been shown to be essential  for
MIF catalytic isomerase activity (Bendrat et al. 1997).
1.5.2. Receptors for MIF:
CD74 is the cell surface binding protein for MIF, which is a form of the
major histocompatibility class II-associated invariant chain, but lacks signal
transduction ability on its own. CD74 is paired with its co-receptor, CD44, as a
signal  transduction  molecule  (Meyer-Siegler  et  al.  2004).  CD74–CD44
activation  leads  to  the  induction  of  pro-survival  signals  in  B-lymphocytes
(Gore  et  al.  2008)  and  MAPK/ERK  pathways  (Lue  et  al.  2006),  and
modulation of JNK (Lue et al. 2011). Activation of the CD74–CD44 cascade
can result both in pro-inflammatory and anti-apoptotic functions. CD74 can
also complex with CXCR2, which leads to increase of adhesion in monocytes
and  neutrophils  by  PI3K  activation  and  T-lymphocytes  ,  leading  to  their
recruitment and arrest (Bernhagen et al. 2007).
CD74 can also bind to CXCR4, which is expressed on immune cells including
T-lymphocytes, monocytes and structural fibroblasts (Schmidt-Supprian et al.
2000). This leads to the activation of JNK MAPK, via the Src/PI3K/JNK/AP1
pathway,  and the induction of  CXCL8 production (Lue et  al.  2011).  At  low
concentration, MIF signals through CD74, which as mentioned before needs
the CD44 for signal transduction, and functions in a pro-inflammatory manner
E f f e c t s  o f  M I F  o n  c h r o n i c  n e u r o i n f l a m m a t i o n 17 
by controlling the transcription of NF-B. This modulates adhesion proteins
and therefore indirectly affects the adhesion of leucocytes (Lee et al. 2012).
At higher concentrations, however, MIF acts via the non-receptor based c-Jun
activation  domain  binding  protein-1  (JAB1),  which  mediates  a  signaling
pathway that leads to a negative effect on inflammation and cell growth (Lolis
et al. 2003).
Extracellular MIF binds to CXCR4 and CXCR2 without the presence of CD74
(Bernhagen et al. 2007). CXCR7 is the most recently identified extracellular
receptor for MIF (Tarnowski et al. 2010). CD74 has also been shown to make
complex with chemokine receptors. CXCR2 and CD74 binding on monocytes,
increases the MIF-induced adhesion of monocytes (Bernhagen et al. 2007).
MIF/CXCR4  activates  AKT  signaling  in  monocytes  and  fibroblasts.
Interestingly, the C-terminal region of MIF is crucial for stabilizing structure of
MIF, but it does not play a role in binding to CD74 (Farah El-Turk et al. 2008).
Intracellular  MIF  (endogenous  intracellular  MIF  and  exogenous  MIF  after
endocytosis) interacts with JAB1 (Kleemann et al. 2000). JAB1 can promote
cell degradation by binding to p27Kip1, which leads to cell cycle arrest. 
1.5.3. Role of MIF in the immune response:
Being discovered as a cytokine secreted by T lymphocytes,  MIF is
thought to have an important role in innate immunity, by acting as a mediator
for  induction  of  other  cytokines  (Bacher  et  al.  1996,  Bozza  et  al.  1999).
However, its role in adaptive immunity is not completely defined and most
reports are from mouse cells or models.
MIF is immediately released from different cell types as a result of exposure
to PARPs (Calandra et  al.  1998),  and acts  as an early stage cytokine by
initiating  the  inflammatory  response  (Bernhagen  et  al.  1993).  As  already
mentioned,  it  can  regulate  the  synthesis  of  many  inflammatory  mediators
(Bacher et al.1996, Mitchell et al., 2002). Inhibition of MIF in murine models
results  in  down-regulation  of  the  cytokine  storm that  follows  LPS-induced
toxicity (Bernhagen et al. 1993). MIF-KO mice are also known to be resistant
to lethal endotoxic shock (Bozza et al. 1999). 
Some of the chemokine like functions of MIF, which are relevant for its role in
the immune response, are listed in the Table 4.
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Initiating  signaling
via:
Resulting in
Endocytosis
 Induced after glucocorticoids overriding
 Interacts with JAB-1 (intracellular receptor)
 Leads to down-regulating MAPK signals
 modulating cellular redox home- ostasis
CD74 receptor
 mediates  signaling  via  CD44  to  induce
activation  of  Src-family  kinase  and
MAPK/extracellular  signal-regulated
kinase (ERK)
 leads  to  PI3K/Akt  pathway  activation  or
p53-dependent inhibition of apoptosis
G protein-coupled 
chemokine receptors
CXCR2 and CXCR4
 binds and signals through alone
 Complex formation of CXCR2 with CD74,
enabling  accessory  binding,  appears  to
facilitate GPCR activation and formation of
a  GPCR-RTK–like  signaling  complex  to
trigger  calcium  influx  and  rapid  integrin
activation
 triggers direct activation of the respective
integrin receptors (eg, LFA-1 and VLA-4)
 Triggers a calcium influx, which induces a
rapid  activation  of  the  integrin  that  can
subsequently mediate the Gi- and integrin-
dependent  arrest  and  the  chemotaxis  of
monocytes and T cells.
Table 4: Chemokine like function (CLF) of the MIF molecule
1.5.4. Association of MIF in different diseases:
Elevated  expression  levels  of  MIF  have  been  shown  in  several
diseases, such as asthma (Rossi et al. 1998), rheumatic arthritis (Leech et al.
1999),  atherosclerosis  (Burger-Kentischer et  al.  2002),  and systemic lupus
erythematosus (Rovensky et  al.  1975).  However,  the  exact  role of  MIF in
these diseases remains to be determined. Many pathogenic events may be
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mediated or induced by the release of  MIF.  Of interest  in this  thesis  is  to
investigate whether MIF is associated with behavioral decline in a sporadic
mouse model of AD.
1.5.5. Inhibition of MIF:
Different  compounds  have  been  used  to  demonstrate  the  anti-
inflammatory effects of MIF inhibition, albeit at differing potencies and acting
via different mechanisms. Inhibition can be achieved by neutralizing anti-MIF
antibodies, but the efficiency of these antibodies decays over time. Therefore,
small molecules inhibitors are generally preferred. 
MIF can be inhibited irreversibly by acetaminophen metabolites (Senter et al.
2002),  benzisothiazolones  (Jorgensen  et  al.  2011),  and  4-iodo-6-
phenylpyrimidine (4-IPP) (Winner et al. 2008).  In particular, the inhibition of
the tautomerase activity of MIF can occur via at least 5 different mechanisms:
[1] binding to the active site, [2] allosteric inhibition, [3] covalent modification
of active site residues,  [4]  disruption of the active site through compound-
induced  dissociation  of  the  active  trimer,  and  [5]  stabilization  of  the  MIF
monomer and prevention of its re-association to form the active trimer.
Recently, ISO-1 has been introduced as a potent inhibitor for the tautomerase
activity  of  MIF.  ISO-1  refers  to  (S,R)3-(4-hydroxyphenyl)-4,5-dihydro-5-
isoxazole acetic acid methyl ester (Fig. 1-3), and has been called the ‘golden
inhibitor’ for MIF because it neutralizes the pro-inflammatory activity of MIF in
vivo and in vitro (Lubetsky et al. 2002). ISO-1 treated mice show enhanced
survival  in the sepsis model of  cecal ligation and puncture (Al Abed et al.
2005).
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1.6. Streptozotocin
We used  intracerebroventricular  Streptozotocin  injection  (STZ-ICV)  as  our
model to investigate our hypothesis.  Briefly,  STZ in the brain leads to the
development  of  insulin-resistant  brain  state,  causing  cognitive  deficit,
specifically  causing  problems  with  spatial  memory,  which  precedes  Aβ
pathology and suggests that this model is appropriate for sporadic AD. To
stay consistent with the in vivo part of the study, STZ was used to stimulate
the glial cells during the  in vitro  studies as well. Streptozotocin (deoxy-2-(3-
methyl-3-nitrosoureido)-D-glucopyranose  (C8H15N3O7)-STZ)  is  a  naturally
occurring antibiotic synthesized by Streptomycetes achromogenes (Fig.1-4),
discovered in 1959.
Figure 1.3.: Molecular structure of ISO-1
 Cell-permeable, a macrophage migration inhibitory factor (MIF) antagonist: ISO-1
inhibits MIF pro-inflammatory activities by targeting MIF tautomerase activity. Also
inhibits  tumor  necrosis  factor  (TNF  )  release from macrophages isolated  from
LPS- treated wild type mice but has no effect on cytokine release from MIF deficient
macrophages (source, Kai Fan Cheng) 
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Figure 1.4.: 2D and 3D structure of STZ molecule.
The molecule has got the molecular weight (MW) of 265 g/mol and is composed of a
nitrosourea moiety (yellow outline) with a methyl group attached at one end (red) and
a glucose molecule at the other (green) Pub-chem: open chemistery Data base.
This molecule shows selective cytotoxicity to pancreatic β cells, and
thus  it  is  used  to  induce  permanent  diabetes  in  murine  models.  Recent
studies  suggest  that  STZ  can  induce  cytotoxicity  by  producing  reactive
oxygen species,  such as superoxide (O2•-),  hydrogen peroxide (H2O2)  and
hydroxyl radical (HO•)  (Uttara et al. 2009). ISO-1 is highly soluble in water,
which  results  in  a  slow  yellow  color,  which  is  a  mixture  of  two  different
anomers.  However,  the  maximum  stability  is  at  pH  4  and  thus  citrate  or
acetate  buffers  are  used  to  prepare  the  solutions  for  STZ.  Even  freshly
prepared  solutions  should  be  used  immediately  for  different  research
purposes (Wold et al. 2006). For our experiments, we used Zanosar, which is
the drug form of the STZ and the powder can be dissolved directly in water.
1.6.1. STZ toxicity mechanisms:
The  following  mechanisms  has  been  suggested  to  explain  the
induction of diabetes by this molecule:
Alkylation  of  cellular  components:  After  entering  the  cell,  STZ  can  be
metabolized and form an isocyanate molecule and a methyldiazohydroxide
molecule (Weiss 1982). The earlier part can affect the intracellular proteins
and  enzymes  via  carbamolyation,  whereas  the  CH3+  section  of
methyldiazohydroxide causes DNA double strand breaks via alkylation that
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leads to cell death (Eleazu et al. 2013). This double break may be repaired if
NAD-dependent  enzyme  poly  (ADP-ribose)  synthetase  (PARP)  is  present
(Lenzen 2008). However, in the pancreatic β cells, the cytoplasm is depleted
of  NAD+,  that  over  time  leads  to  loss  of  ATP,  which  ultimately  leads  to
pancreatic cell death (Cnop et al. 2005) and permanent diabetes in murine
models (Piepper et al. 1999). PARP deficient mice are shown to be resistance
to STZ cytotoxicity (Masutani M et al.1999).
Nitric  oxide  (NO)  release:  As  mentioned  before,  the  STZ molecule  is  a
nitrosureas, which means it can release NO molecule. NO molecule causes
DNA damage (Wada, Yagihashi 2004). The NO detected in the cell after STZ
stimulation mainly is released from the STZ molecule and not as a result of
catalytic processes in the cell, since it is not inhibited following application of
NOS inhibitors (Kronche et al. 1995). 
Generation of free radicals leading to oxidative stress: Free radicals such
as superoxide radical (O2◦-), hydroxyl radical (OH◦-) are also produced after
STZ  injection  (Qinna,  Badwan  2015). Auto  oxidation  of  the  glucose,  and
glycation  of  the  proteins  as  a  result  of  the  presence  of  free  radicals,  is
followed by oxidative stress (Matough et al. 2011).
O-GlcNAcase inhibition: STZ can produce extreme damage to the islet  β-
cells  by inhibiting O-GlcNAcase (OGA) (Ischiropoulos al-Mehdi  1995).  The
STZ  molecule  has  a  selective  cytotoxicity  for  pancreatic  β  cells,  thus  is
frequently  used  to  induce  diabetes  in  murine  models.  However  in  sub-
diabetogenic doses it can induce damages to insulin receptors (IR) followed
by insulin resistance. In this case also cognitive deficits has been observed as
well  as  tau  and  Aβ  pathology,  suggesting  that  this  molecule  is  linked  to
sporadic AD (Watson GS et al. 2003).
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1.7. Neuroinflammation as a risk factor for cognitive deficit
Despite  the  efforts  to  elucidate  specific  mechanisms  underlying
neurodegenerative  diseases,  the  ethiopathogenesis  is  yet  not  completely
understood.  It  seems  that  a  combination  of  many  central  and  peripheral
factors might  play a  role  in  the  progression of  these conditions.  Although
neuroinflammation is unlikely to be the triggering factor, it likely contributes to
the  progression  of  neurodegenerative  diseases  (Migliore,  Coppede  2002).
Studies  indicate that  chronic  activation  of  glial  cells  in  the  CNS,  which is
followed by constant elevated level of cytokines in many neurodegenerative
disorders such as AD (Cartier et al. 2005), occurs in advance to the neuronal-
loss  stage  (Frank-Cannon et  al.  2009),  however  in  humans  symptoms of
cognitive decline will be manifested when already massive neuronal loss took
place. Therefore it is necessary to investigate the possible mechanisms that
are involved in progression of neuroinflammation. Chronic inflammation is one
of the characteristics of neurodegenerative diseases. Inflammatory processes
in different sites of the brain such as hippocampus and cortex leads to loss of
function or death of the cells in those areas, resulting in significant behavioral
deficits. Increase in hippocampal expression of certain cytokines (IL1-β, IL6,
TNF-α)  is  paralleled  by  cognitive  impairments  such  as  spatial  memory
problems. Different studies demonstrate that almost 40% of elderly (above 65
year)  can be diagnosed with  some extend of  memory impairment  (Peters
2006). It has been shown that infusion of D-APV (NMDAR inhibitor) disrupts
many cognitive responses, such as the acquisition of contextual fear (Matus-
Amat et al. 2007) and spatial memory. In vivo experiments in rats showed that
ICV injection of IL-1β leads to reduction of TNF expression and impairment of
hippocampal-dependent memory (Barrientos et al. 2004). Of interest to this
thesis  is  the  regulatory effect  of  the  small  cytokine MIF  in  controlling  the
expression  of  the  inflammatory  mediators  and  how  it  could  contribute  to
neurodegeneration and cognitive deficit. In our model, STZ is injected into the
hippocampus, which leads to chronic inflammation and neurodegeneration in
the area followed by memory deficits.  The spatial  cognitive impairments is
tested in the clockmaze task, and the expression levels of different cytokines
are tested in the hippocampus.
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1.7.1. The hippocampus and spatial memory: 
Memory is the mental representation of “where”, “when” and “what”, of
the events that have been experienced in the past. It can be divided in many
types and many specific parts of brain function together to make this mental
time travel possible. The information of “where” in episodic memory, referred
to  as  “spatial  memory”,  is  provided  by  the  neurons  in  the  hippocampus.
Spatial memory, which is defined as the ability to gain and retain information
about the position or location of places and objects, declines during many
neurodegenerative  conditions  in  the  brain.  The  hippocampus  is  the  major
area of the brain associated with spatial memory function (Ryan et al. 2010).
This bilateral and symmetrical structure is located in medial temporal lobe of
the brain and is a part of the limbic system, and is critical for encoding spatial
memory.  Hippocampal  place  cells,  first  discovered  by  O’Keefe  and
Dostrovsky in 1971, are involved in the spatial mapping experience in many
animals. Place cells, which are considered memory cells are necessary for
encoding  the  spatial  information  in  mice  (Cabral  et  al.  2014),  chimps
(Matsumura  et  al.  1999)  and  humans  (Ekstrom  et  al.  2003).  Plasticity  is
another mechanism involved in learning and memory. Spatial learning can be
disrupted  by  blocking  the  N-methyl-D-aspartate  receptors  (NMDARs)
(Caramanos, Shapiro 1994; Steele, Morris 1999), which results in failure of
encoding new memories.
1.7.2. Anatomy of the hippocampus: 
Hippocampus is located in the medial temporal lobe, and is divided
into two “U”  shaped parts.  The hippocampal  formation is  made up of  five
structures (Amaral et al.  1995):  [1]  hippocampus proper,  [2]  subiculum, [3]
presubiculum, [4] parasubiculum, and [5] entorhinal cortex. The hippocampal
formation, that was thought to be a part of olfactory section for a long time,
plays an important  role in  spatial  memory and learning.  The hippocampus
proper can be subdivided into three areas named CA1, CA2, CA3 followed by
dentate gyrus (DG).
Numerous  afferent  and  efferent  neurons  in  this  structure  cooperate  to
integrate data on environment, emotions and motivations into spatial memory.
The main cells are organized into a single and densely packed layer, which
makes them an interesting target for electrophysiological studies. Indeed, in
1971,  electrophysiological  recordings  by  Doskrovsky  et  al.,  showed  that
specific  cells  start  firing  as  a  rat  enters  a  restricted  area  from a  familiar
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environment,  which  lead  to  publishing  "The  Hippocampus  as  a  Cognitive
Map"  by  John  O'Keefe  and  Lynn  Nadel  in  1978.  The  structure  of
hippocampus is well conserved between humans and rodents, and rodents
can experience similar deficits in spatial  memory, which has made them a
highly used model for age-related memory decline. 
Figure 1.5.: Structure of hippocampus
Top:  The hippocampus is placed medial temporal lobes, this part of brain is
necessary for forming new memories (Bird and Burgess, 2008). 
Bottom: The neural circuitry in hippocampus (Berridge et al., 2012, modified).
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1.7.3. Fear and context memory
Fear can be innate and genetically encoded,  or  it  can be acquired
through unpleasant experiences, which leads to the activation of autonomic
nervous system, associated with higher adrenaline levels and “flight or fight
response” (Kozlowska et al. 2015). Fear memories are created as a result of
interaction between different neural systems in the brain. The hippocampus
and the amygdala are two independent structures placed in temporal lobe
that  cooperate  in  fear  dependent  memory formation.  The hippocampus  is
responsible for acquiring the information about the environmental contexts,
which  function  as  cues  that  allow  subjects  to  recover  the  information
associated with the experiences. These signals are processed and turned into
a  conditioned  response  (CR)  by  amygdala  (Phelps  et  al.  2004).  Some
experiences carry emotional burden to a level that the subject would evoke
the whole emotional experience (Smith, Bulkin et al. 2014).
Contextual fear conditioning is defined as demonstration of fear in a context
that has previously provoked fear in the subject  (Baas et al. 2004). Context
itself is defined as a set of cues surrounding a specific situation.
Classical  (Pavlovian)  fear  conditioning  is  often  used  to  investigate  this
emotional experience. The experiment consists of the combination of a non-
emotional  stimulus  (conditioned  stimulus:  CS,  in  our  case  a  tone)  and
aversive stimulus (Unconditioned stimulus, US, we used foot shock). Animals
are exposed to this pairing, and over time a conditioned response is formed
(CR),  where  the  animal  reacts  to  CS without  the  presence  of  US,  which
indicated the existence of  an association between CS and US.  In murine
models the word “Fear” doesn’t necessarily mean “being afraid”, but refers to
changes  in  behavioral  performance  such  as  suppression  of  appetite  and
freezing  (Blanchard  et  al.  1989),  which  can  be  objectively  measured.
Reaction happens as a  result of re-experiencing the same context (being in
the same chamber, Goosens et al. 2003; Wang et al. 2012).
The amygdala  plays  the central  role  in  this  reaction,  however  undeniable
evidence indicates that proper function of the hippocampus is also involved in
developing  this  emotional  reaction  in  response  to  contextual  information
(Bouton,  Moody  2004;  Hobin  et  al.  2003).  The  interaction  between  the
amygdala and the hippocampus reinforces the memories of emotional events
(Phelps et al. 2004). It  seems that stress hormones released by amygdala
following  a  fearful  situation,  modulate  the  consolidation  of  the  contextual
memory (Cai et al. 2006, McGaugh, Roozendaal 2002). For this reason, the
E f f e c t s  o f  M I F  o n  c h r o n i c  n e u r o i n f l a m m a t i o n 27 
hippocampus  has  been  the  target  of  several  studies  investigating  the
contextual acquisition and extinction of fear conditioning, but also the retrieval
of the fearful memories. There is also enough evidence to confirm that the
hippocampus is also involved in extinction of fear conditioning (Bouton et al.
2006). It is interesting to note that, the proper CS differs for different species.
For examples, in murine models, animals are capable of associating a tone
with shock, whereas they fail to associate taste as CS with shock (Tracy et al.
2004).  Therefore,  fear  conditioning  is  considered  a  reasonable  model  to
examine  the  neuronal  circuitry  involved  in  the  processes  that  control  an
animal’s  response  to  aversive  stimulus  combined  with  a  cue.  With  these
experiments we aim to examine the fear conditioning when the hippocampus
bears chronic inflammation, hypothesizing that the amygdala is not affected.
1.7.4. Fear pathways in the brain:
The  neural  circuitry  that  is  critical  for  acquiring,  processing  and
responding to fear requires the involvement of key areas of the brain including
the  amygdala,  the  prefrontal  cortex  and  the  hippocampus.  Briefly,  the
hippocampus records the incoming contextual cues, it is the memory center
that  stores  information  from  different  senses  along  with  their  emotional
weight, and then signals to the amygdala, which is the emotional core of the
brain, and has the primary role in triggering the fear response.
The  amygdala  is  a  small  structure  of  grey  matter,  located  in  the  medial
temporal  lobe.  The  structure  was  first  described  in  relation  to  studies  of
Klüver-Bucy  syndrome  (Gaul  et  al.  2007) and is  involved  in  processing
emotions. Weiskrantz’s (1956) study demonstrated that this structure plays a
pivotal role in avoidance behavior in response to fear in monkeys (Weiskrantz
1956). In other words, the emotional load of an event can be interpreted into
fear with the help of the amygdala. It plays a central role in the circuitry for the
expression of fear (Ledoux 2015, Rauch et al. 2006). It is also involved in the
synaptic connections that are critical  for both acquisition and storage of the
fear-related memories (Melia et al. 1992; Debiec, Ledoux 2004). 
The amygdala  plays  a role  in  influencing hippocampal-dependent  memory
(Bass et al.  2014). The hippocampus is the brain center in which emotion
overlaps  with  memory.  The hippocampus is  mainly  involved in  processing
episodic memory. It is responsible for generating declarative representations
of the emotional events that are stored by amygdala as fear memories
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(Phelps,  et  al.,  2004).  However,  memory after  a  certain  period  of  time is
stored in neocortex and becomes independent of the hippocampus (Young et
al., 1994). In the case of contextual memory, the hippocampus plays a role in
processes that underlie the acquisition and consolidation of contextual fear.
This  process most  likely involves NMDA receptors (Sanders  et  al.,  2003).
Despite all evidence indicating that different hippocampal ensembles seem to
be involved in encoding these memories (Smith & Bulkin, 2014), it has been
difficult to establish a direct causal link between the neural firing and memory
formation up to now.  Foot-shock is  the  golden standard aversive stimulus
used for contextual fear conditioning since 1980. A single exposure to this
stimulus  is  followed  by  immediate  freezing  reaction  in  the  animals.  As
mentioned earlier, different areas of the brain, such as the amygdala and the
hippocampus,  are  involved  in  shock-induced  fear  conditioning.  The
hippocampus, the perirhinal cortex and the basolateral and central nucleus of
the amygdala  (BLA,  CeA)  seem to  play a  role  in  the  foot  shock reaction
(Sacchetti  et  al.  1999).  The neurobiology of  the footshock is  explained in
Figure 1-6.
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Figure 1.6.: Fear conditioning pathways.
Top:  Scheme  of  the  fear  conditioning  circuit  involved  in  contextual  fear
conditioning: hippocampus plays the central role in acquisition of the information.
Amygdala: LA, Lateral, BL, basolateral, BM, baso-medial, CE, central nucleus.
Hippocampus:  CA1,  CA3 regions,  DG,  Dentate  Gyrus.  Ent:  Entorhinal  cortex.
PAG: Periaqueductal Gray
Bottom: In this task, the animal learns to pair the tone (CS) with the foot-shock
(US), US-CS combinations are paired in the lateral amygdala (LA). To be specific,
tone information is delivered to LA by passing medial geniculate body (MGN) and
the foot shock data is delivered by posterior intralaminar nucleus (PIN), resulting
in neuronal plasticity. These neurons are activated in response to subsequent
presentation of the tone, by signaling central nucleus (CN), which mediates the a
reactive response (freezing) or an active one (escape or avoidance)
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1.8.Systemic factors involved in cognitive impairment:
 For the purpose of explaining the role of systemic factors in causing
memory  deficits,  the  focus  have  mainly  been  on  AD,  which  is  the  most
common form of dementia. Mutations in certain genes may explain the onset
of some of neurodegenerative conditions such as the familial form of AD, but
factors triggering the late onset AD are still not fully understood. Adults with
normal cognition may have markers of neurodegenerative disease but appear
to  be  healthy  (Kirk-Sanchez,  McGough  2014).  This  is  referred to  as
Suspected Non-Alzheimer Pathophysiology (SNAP) and is not considered a
pre-clinical  stage (Graff-Radford et  al.  2016).  Based on documentation on
SNAP cases up to ¼ of cognitively normal adults exhibit neurodegeneration.
Markers  in  PET  scans  and  MRI  of  hippocampus  (Leung  et  al.  2015).
However,  certain systemic manifestations are considered to be associated
with, or instigate AD and vascular dementia or accelerate their progression.
Obesity,  diabetes  mellitus  and  hypertension  as  well  as  pathogenic
mechanism such as inflammation can increase the risk of cognitive deficits.
These processes can lead to hippocampal damage or increase in CSF tau,
which  acts  as  a  risk  factor  to  trigger  the  neuroinflammation  leading  to
neurodegeneration. 
1.8.1 Systemic inflammation
It  has  been  shown  that  peripheral  immune  cells  can  contribute  to
neuroinflammation. Once in the brain these peripheral cells activate microglia
and  astrocytes,  leading  to  cytokine  production,  which  can  disrupt  normal
processes in the brain, for instance triggering APP synthesis and Aβ formation
in the case of AD. This results in further production of cytokines followed by
neurotoxicity. Inflammation associated pathologies happen proximately in the
site of activated glial cells (Saijo et al. 2010), but are not limited only to the
brain. Measurement of chemokines and cytokines in the serum show elevated
levels of certain biomarkers in the periphery especially in cerebrospinal fluid
(CSF) (Humpel, Hochstrasser 2011). 
The expression of adhesion molecules on BBB is increased in response to
neuroinflammation or as a result of aging, also the expression of macrophage
inflammatory protein-1α (MIP-1α) is increased in peripheral T cells, which in
return  leads  to  over  expression  of  CCR5  on  brain  endothelial  cells.  The
interaction  between  these  two  facilitates  brain  infiltration  for  the  T  cells
(Mildner et al. 2007).
E f f e c t s  o f  M I F  o n  c h r o n i c  n e u r o i n f l a m m a t i o n 31 
1.8.1.1 Effect of cytokines on cognition:
Cytokines such as IL-6, IL-1β and TNFα are released from microglia
and astrocytes at a significantly higher level during inflammation (Zhang, An
2007), which as a part of normal response may play an essential role as a
part of behavioral processes, however in chronic form it leads to deficits in
different behavioral and performance abilities. It has been reported that the
sustained  increase  in  TNF-α  is  associated  with  decrease  in  cognitive
performance  of  AD  patients  (Holmes  et  al.  2009).  Transgenic  mice  that
overexpress IL-6 exhibit disturbances in cognition (Akiyama et al. 2000), and
there is a sustained elevation in IL-6 levels in  the nigrostriatal  region and
cerebrospinal fluid (CSF) of PD patients (Kunze et al. 2008). Chronic cytokine
elevation  can lead  to  behavioral  deficits  such  as  impairment  in  cognition,
which  is  observed  in  preclinical  stage  of  AD  (Guerreiro  et  al.  2007),
suggesting the possible correlation between cytokine levels and prevention in
proper  function  of  normal  cognitive  processes  to  the  extent  of  dire
consequences.  Based  in  these  observations,  many  groups  have  tried  to
establish  a  cognition  deficit  rodent  model  by  inducing  and  sustaining  the
cytokine  production  on  CNS.  Cognitive  impairments  have  been  observed
upon  intracerebroventricular  (ICV)  injection  of  IL-6  into  hypothalamus.  In
1993,  Otzil  and  his  group  injected  IL-1β  intracerebroventricularly  (ICV)  to
induce memory deficit that was studied by Morris Water Maze Task (MWM).
All these cytokines, however, cross-induce each other and are expressed in
an overlapping spectrum.  Therefore,  ICV injection  of  only  one  cytokine  is
good for investigating the effects of that specific cytokine, but is inappropriate
for  inducing  neuroinflammation  as  a  neurodegenerative  disease  model.
Alternatively, lipopolysaccharide (LPS) is often used as central inflammatory
stimuli to affect dopaminergic neurons, but the effects are transient and do not
induce neurodegeneration  (Glass et al. 2010). ICV injection of STZ, on the
other hand,  can induce cognitive deficit  through inflammatory mechanisms
that affect the cell survival and neuronal properties in the hippocampal area
and recapitulate the cognitive deficits that are common in neurodegenerative
diseases,  such  as  dementia  in  AD.  STZ-ICV  is  shown  to  induce
neuroinflammation,  mimicking  many  aspects  of  sporadic  AD,  and  also
exhibiting  some  behavioral  deficits  such  as  impaired  learning  and  spatial
memory (Kaushal et al. 2013). STZ ICV in the brain leads to upregulation of
GFAP and Iba-1 markers,  which label  for  respectively activated astrocytes
and microglia in the brain.
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Additional  studies  are  necessary  to  determine  the  factors  responsible  for
shifting the inflammatory response from being neuroprotective to neurotoxic.
Several paradigms have been designed to show and evaluate spatial memory
capacities and deficits in murine models. In 1982, Morris et al, used Morris
Water Maze (MWM) as an experimental paradigm in animals suffering from
hippocampal lesion to show their impaired ability in spatial learning The 8 arm
radial maze by Olton and Samuelson is another frequently used paradigm to
test reference and the working memory. However, for the purpose of testing
spatial memory in this thesis,  we decided to use the clockmaze paradigm.
Clockmaze is similar to MWM for using water as an stimulus for animals to
escape the maze by using their spatial navigation capacities as they attend to
several  visual  cues  (external  to  the  maze)  to  solve  the  paradigm.  The
clockmaze  avoids  the  hostile  condition  of  deep  water,  so  the  element  of
aversion is not used as motivation. Parameters such as “latency”, “strategy
used  to  escape  the  maze”  and  “number  of  errors”  are  measured  by  this
experiment.
1.9. Effects of STZ-ICV related neuroinflammation on context memory
Impaired glucose metabolism in patients with type 2 diabetes, in mid
and late life,  can be a risk factor  for cognitive decline,  as shown by twin-
population  based  studies  (Barbara  Caracciolo  et  al.  2013).  Recent
epidemiological studies suggest that diabetes mellitus is a strong risk factor
for memory impairment.  Investigations are ongoing to study the interacting
mechanisms between these conditions. Serious loss of cognitive ability and
spatial  disorientation  are  the  common  characteristics  of  many  forms  of
dementia  including  AD,  which  is  the  most  common  form  of
dementia.Repetitive  intraperitoneal  injection  of  STZ  is  used  to  cause
permanent diabetes mellitus in murine models. It was recognized after a while
that these injections are followed by impaired neuronal plasticity and learning
deficits (Stranahan et al. 2008). When administered at low sub-diabetogenic
doses,  STZ could  still  cause insulin  resistance in  the brain (Kamat  et  al.,
2015)  by playing a role  in  decrement  of  brain  glucose/energy metabolism
(Shah et al. 2012) and oxidative stress induction (Anwar et al. 2003). It also
induced  cognitive  and  brain  cholinergic  deficits  (Pawel  Grieb,  2015).
Intracerebroventricular (ICV) application of the streptozotocin (STZ) is now a
widely accepted model of neuroinflammation and neurodegeneration (Chen et
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al. 2012). The purpose for the STZ-ICV model in this study is to investigate
the  effects  of  chronic  inflammation  on  neurodegeneration,  and  cognitive
deficits, which is critical for putting the novel therapeutic approaches against
these problems to the test.
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2. Specific Aims
The  symptomatology  of  neurodegenerative  diseases  such  as
Alzheimer and Parkinson has been extensively characterized, but the search
for  a  cure  has  not  been  successful  yet.  These  conditions  are  classically
characterized  by  protein  aggregations  (plaques  and  tangles),  which  have
become  targets  for  the  current  therapeutic  approaches.  Sadly,  these
strategies have failed to slow disease progression. These failures have led
researchers  to  consider  other  pathological  mechanisms  leading  to
neurodegeneration.  Among  these,  chronic  inflammation  of  brain  cells  has
received increasing attention as a strong candidate for novel therapies.
In  this  thesis  we  interrogate  the  role  of  macrophage  migration
inhibitory factor (MIF) in neuroinflammation, and the effects of obstructing this
molecule as a putative anti-inflammatory strategy. The specific aims include: 
1. To  investigate  in  vitro whether  the  inhibition  of  MIF  can  halt  the
secretion  of  pro-inflammatory cytokines  by inflamed astrocytes  and
microglia.  We study murine cells in culture, challenge them with an
inflammatory signal, and determine their cytokine profile (using ELISA
and Western blots) in control conditions vs. MIF inhibition.
2. To investigate in vivo whether the inhibition of MIF can ameliorate the
innate immune response, as well as cognitive and behavioral decline,
which occur during brain inflammation. We use the mouse model of
intra-cerebro-ventricular  injection  of  streptozotocin  (ICV-STZ)  to
induce  neuroinflammation.  We  inhibit  MIF  with  intra-peritoneal
application  of  ISO-1.  We  measure  behavioral  performance,  pro-
inflammatory cytokines (using real time quantitative PCR, qPCR), and
the expression level of astrocytic and glial activation markers, GFAP
and Iba1 by immunohistochemistry.
3. To investigate whether MIF-KO mice, with complete MIF deficiency,
represent  a  reasonable  model  to  complement  the  studies  of  brain
inflammation and MIF. We study, in vivo and in vitro, the responses of
MIF-KO mice to the STZ inflammatory agent. 
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3. Materials
3.1. Buffers and solutions
The following buffers and solutions are used in this study
Buffer Composition
0.5 M EDTA  186,1 gr EDTA (with Na)
800 ml H2O
20 gr NaOH
,pH 8, ad 1L with H2O
50X TAE (electrophoresis 
buffer for DNA)
Tris Base 242gr
HCl 75,1 ml
0,5 EDTA (pH 8) 100ml
Radioimmunoprecipitation 
assay buffer
(RIPA) Lysis Buffer
1% NP-40 detergent
0,1% SDS
50mM Tris-HCl pH 7.4
150mM NaCl
0,5% Sodium deoxylate
1mM EDTA
Reaction buffer (cDNA 
synthesis)
Produced by thermo scientific
Denaturing solution (solution 
D) 
- trizol protocol
4 M Guanidinium thiocyanate
25 mM Natriumcitrat pH 7,0
0,5% (wt/vol) Sarkosyl
0,1 M 2-Mercaptoethanol
2M Sodium Acetate pH 4,0
- trizol protocol
16,42g Sodium Acetate (water free) to 
40 ml DEPC-H20
+35 ml Acetic Acid, set pH value on 
4.0 (using Acetic Acid)
Fill up to 100mL using DEPC-H20
Water saturated Phenol
- trizol protocol
 Solve 100 g of Phenol cristals in aqua
dest at 65°C 
discard the flow
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Chloroform:Isoamyl alcohol 
(49:1)
- trizol protocol
49 ml Chloroform + 1 ml Isoamyl-
alcohol vermischen
Diethylpyrocarbonate DEPC-
H2O
- trizol protocol
Add 1 ml DEPC to 1l H20
Mix
2x Autoclave 
75% Ethanol 75 ml absolute Ethanol + 25 ml DEPC-
H20
wash buffer (murine MIF Elisa) PBS containing 0.05% Tween-20, pH 
7.4
reagent diluent (murine MIF 
Elisa)
1% BSA in PBS pH 7.4
Substrate buffer
(murine MIF Elisa)
7.3 g citric acid x H2O (C6H8O7)
11.87g NA2HPO4 X 2H2O
Ad 1L H2O, pH value of 5.0
sterile Tris buffered saline 20 mM Trizma base
150 mM NaCl
0.1% bovine serum albumin
Gel electrophoresis Stacking 
gel buffer
30g Tris HCL
2g SDS
Ad 500ml water
Gel electrophoresis separating
gel buffer
186g Tris
4g SDS
Ad 1l water, pH 8.8
Western Blot membrane 
stripping buffer(mild)
15 g glycine
1 g SDS
10 ml Tween20
Adjust pH to 2.2
Bring volume up to 1 L with ultrapure 
water
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Coomassie blue dye solution 0.1% Coomassie brilliant Blue R-250, 
50% methanol and 10% glacial acetic 
acid
FACS buffer 1x PBS without 
Ca/Mg 
500 ml
3% fetal calf serum 
(FCS)
15 ml
0.01% Azide 500 µl
0,1 M citric acid Dissolve  1.05  g  of  citric  acid
monohydrate  in  50  ml  ddH2O  and
store at room temperature.
0,1 M sodium citrate Dissolve  1.47  g  of  sodium  citrate
tribasic dehydrate in in 50 ml ddH2O
and tore at room temperature.
Solution D 4 M guanidinium thiocyanate 
25 mM sodium citrate 
pH 7.0 
0.5%  (wt/vol)  N-laurosylsarcosine
(Sarkosyl) 
0.1 M 2-mercaptoethanol 
Prepare stock with: 
dissolving  250  g  guanidinium
thiocyanate in 293 ml water at 65 °C 
add 17.6 ml of 0.75 M sodium citrate,
pH 7.0 
26.4  ml  of  10%  (wt/vol)  N-
laurosylsarcosine 
(stored  <  3  months  at  room
temperature)
Working solution from stock: 
add  0.36  ml  of  98%  2-
mercaptoethanol  to  50  ml  of  stock
solution (store <1 month at RT) 
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Citrate Buffer Preparation:  fresh  in  the  morning  by
combining  20  ml  of  0.1  M  Sodium
citrate with 30 ml of 0.1 M Citrate acid
to produce 0.1 M Citrate buffer. Adjust
the  pH  to  4.5  by  using  1  N  NaOH.
Filter-sterilize  the  Citrate  buffer  and
store it in a sterile conical tube on ice.
 3.2. Kits
 Following kits have been used for this study
Kit Function Source
GeneJET Plasmid 
Maxiprep kit
Isolation of high copy
numbers of plasmid 
DNA
Thermo scientific
#K0491, #K492
QIAamp DNA Blood 
Mini Kit
purification of up to 
12 µg genomic, 
mitochondrial, or 
viral DNA from blood 
and related body 
fluids
QIAgen
Cat.No. 51104
GeneJet Plasmid 
Miniprep kit
Thermoscientific
NucleoBond® Xtra 
Midi EF
MACHEREY-NAGEL 
GmbH & Co
QIAamp®DNAMini QIAGEN
GeneJET PCR 
Purification Kit
Thermo Fisher 
Scientific #k0701
peqGOLD Gel 
Extraction Kit
PeqLab
LDH Cytotoxicity 
Assay
Thermo Scientific
XTT Life theconologies
QIAamp DNA Blood 
Mini Kit (50)
For DNA minipreps Cat. No. 51104
Qiagen
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3.3. Primers
Following primers have been used for this study:
Primer Sequence
murine MIF F CCATGCCTATGTTCATCGTG
murine MIF R GAACAGCGGTGCAGGTAAGTG
murine IL-12a F ATGATGACCCTGTGCCTTGG 
murine IL-12a R CACCCTGTTGATGGTCACGA
murine DDT F ACCGGATCGTTATCCGCTTC
murine DDT R AGTCGCAGACGTTTAGGCAA 
Mu.IL-12b F TCGCAGCAAAGCAAGATGTGT
Mu.IL-12b R CGTGAACCGTCCGGAGTAAT
mIl6 F ACAAGTCCGGAGAGGAGACT
mIl6 R GTCTTGGTCCTTAGCCACTCC
mTNF F CTATGGCCCAGACCCTCACA
mTNF R AAGTAGACGTGCCCGGACTC
mIl-12aF GGTGAAGACGGCCAGAGAAA
mIl-12aR AGATGCTACCAAGGCACAGG
mIl-10F CAGTACAGCCGGGAAGACAA
mIl-10R CCTGGGGCATCACTTCTACC
m IL-1βF CAACCAACAAGTGATATTCTCCATG
m IL-1βR GATCCACACTCTCCAGCTGCA
mCD74 F CGAGGCTCCACCTAAAGAGC
mCD74 R CGTGTCCTGGGACGATGAAA
mCD44 F CTGTCATACACTGGTCCGGG
mCD44 R CTTGGCCACCACACAGAGTC
mCXCR2 F TGCTACTAGCCTGCATCAGC
mCXCR2 R AGACAAGGACGACAGCGAAG
mIL-27 p28 F CTCTGCTTCCTCGCTACCAC
mIL-27 p28 R GGGGCAGCTTCTTTTCTTCT
mIL-15 F AGGTCCTCCTGCAAGTCTCT
mIL-15 R TGCTTTGAAGAGCCAGAGGG
murine TLR4 F AGCTTGAATCCCTGCATAGAGGTAG
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murine TLR4 R ATTTTGTCTCCACAGCCACCAG
murine CXCR3 F ACAGCACCTCTCCCTACGAT
murine CXCR3 R AATCTGGGAGGGCAAAGAGC
qPCR primers
muBACTIN CTAAGGCCAACCGTGAAAAG
re_muBACTIN ACCAGAGGCATACAGGGACA
mu_IL6 GCTACCAAACTGGATATAATCAGGA
re_mu_IL6 CCAGGTAGCTATGGTACTCCAGAA
mu_IL1b AGTTGACGGACCCCAAAAG
re_mu_IL1b AGCTGGATGCTCTCATCAGG
mu_TNFa CTGTAGCCCACGTCGTAGC
re_mu_TNFa TTTGAGTCCATGCCGTTG
muIFNb GCACTGGGTGGAATGAGACT
re_muIFNb AGTGGAGAGCAGTTGAGGACA
muINFa TCTGATGCAGCAGGTGGG
re_muINFa AGGGCTCTCCAGACTTCTGCTCTG
muIL-12p35 CACCCTTGCCCTCCTAAACC
re_muIL-12p35 CACCTGGCAGGTCCAGAGA
muIL-12p40 ACAGCACCAGCTTCTTCATCAG
re_muIL-12p40 TCTTCAAAGGCTTCATCTGCAA
muIba1 GGATTTGCAGGGAGGAAAAG
re_muIba1 TGGGATCATCGAGGAATTG
muGFAP TCCTGGAACAGCAAAACAAG
re_muGFAP CAGCCTCAGGTTGGTTTCAT
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3.4. Media and cells
The following media are used in this study:
3.4.1. Iscove's Modified Dulbecco's Medium (IMDM): 5% bovine serum, 1% L-
glutamine (200 mM), 1% penicillin-streptomycin; source: Neuro-Zone.
3.4.2.  Opti-MEM®  I  Reduced  Serum  Media:  10%  FCS;  1%  penicillin-
streptomycin; 0.01% mercaptoethanol; source: Life Technologies.
3.4.3. Roswell Park Memorial Institute medium, RPMI 1640: 10% FCS, 1%
penicillin-streptomycin,  1%  L-glutamine,  1%  Amino  acid  cocktail;
source: Life Technologies Cat# 11875-093.
3.4.4. LB-Agar (Lennox): Trypton, 10 g/l; Hefeextrakt, 5 g/l; NaCl, 5 g/l; Agar-
agar, 15 g/l; pH 7.0; source: Roth
3.4.5. LB Broth (Lennox): Tryptone, 10 g/l; yeast extract, 5 g/l; NaCl, 5 g/l; pH
7.0 ±0.2; source: Roth.
3.4.6. Hank's Balanced Salt Solution (HBSS): HBSS, calcium, magnesium, no
phenol red; source: Life Technologies
3.4.7.  Dulbecco's  Modified  Eagle  Medium  (DMEM):  low  glucose,  sodium
pyruvate,  GlutaMAX™, Phenol  Red;  source:  Life  Technologies  Cat#
10567014
The following cells are used in this study:
3.4.8. N9 microglial (IMDM)
3.4.9.  Immortalized  macrophage  cell  line  (Opti-MEM®  I  Reduced  Serum
Media)
3.4.10. RAW macrophages (RPMI)
3.4.11. DH5 alpha Competent E. coli cells (LB and LB-A)
3.4.12. SH - SY5Y human neuroblastoma (DMEM)
3.5. Chemicals
Chemical Source
MIF recombinant mouse Protein
Life Technologies Cat# 
50066-MNAE-25
Human MIF Biotinylated Antibody R&D Systems Cat# BAF 289
Anti MIF antibody ABcam Cat# ab7207
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RiboLock RNase Inhibitor Thermo Scientific
Reverse transcriptase Thermo Scientific
Complete Protease Inhibitor Cocktail 
Tablets
Roche Cat. No. 11 836 153 
001
Anti-mouse TNF-  antibody
eBioscience Cat. No. 51-
26731E
Biotinylated anti-mouse TNF-  antibody 51-26732E, BD Bioscience
Murine TNF- R&D, Nr. 410-MT
Streptavidin POD
Roche, Cat-No : 11 089 153 
001
Anti-mouse il-6 antibody R&D, Cat-No: MAB 406
Biotin-rat anti-mouse IL-6 R&D, Cat-No: BAF 406
Murine IL-6 R&D, Cat-No: 406-ML
Rat anti-human IL-6 Pharmingen, Cat-No 554543
Biotin rat anti-human IL-6
Pharmingen, Cat-No: 
554546
Human IL-6
Immuno-tools, Cat-No: 
11340064
anti-mouse IL-12p40/p70 BD#551219
Recomb. mouse IL-12p40 Biolegend # 573102
Biotin anti-mouse IL-12p40/p70 BD#554476
β-amyloid (Aβ1-42) Invitrogen, Carlsbad, CA 
Anti CD11b antibody [M1/70] abcam CAT. No. # ab8878
Anti-ACSA-2 antibody
MACS miltenyi biotec order 
No. 130-102-365
Bovine Serum Albumin (diagnostic 
grade)
Millipore Cat# 82-045-1
Guanidium thiocyanat Roth
Natriumcitrat Roth
Sarkosyl Sigma
2-Mercaptoethanol
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Natriumacetat(water free) Roth
Acetic acid Roth
Phenol (nucleic acid grade) Roth
Chloroform
Isoamyl Alkohol Roth
Isopropanol Roth
Ethanol Roth
DEPC Roth
100 bp DNA ladder thermo scientific
6x DNA loading 100 bp thermo scientific
SuperSignal West Femto Substrate thermo scientific Cat# 34095
RapidStep™ ECL Reagent Calbiochem Cat# 34581
Sodium chloride  ROTH CAS-No. [7647-14-5]
SDS Pellets ROTH
IGEPAL® CA-630 Sigma, CAT# I8896-100ML
Sodium deoxycholate Sigma
TRIS PUFFERAN® ≥99,9 %, p.a. ROTH, CAS-Num [77-86-1]
10X DreamTaq Buffer
Thermo scientific lot# 
00125872
Dream taq DNA polymerase 
Thermo scientific lot# 
00140114
Nuclease Free water
Thermo scientific lot# 
00143631
dNTP mix Thermo scientific lot# R0191
citric acid Sigma C1909, MW 210.14
sodium citrate Sigma C0909, MW 294.10
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3.6. Devices
Product Source
Cell Culture Dish BD Falcon™ Cat# 353003 
6 well Culture plate
Greiner CELLSTAR® Cat# 
65160
Double net ruling Fuchs Rosenthal 
Counting Chamber
Neubauer Germany
Thermo-shaker TS-100
GmbH
automated plate washer Thermo Scientific
stir bar, VWR, 7*2mm,
Kallestad ,Cat. Nr. 58948-
976
Speedvac, Vacuum concentrator
magnetic stirrer
Protein LoBind Tubes
Eppendorf order Nr. 0030 
108.116
Sonicator 
spectrophotometer ND 1000 Thermo Scientific
Strile work bench HLC BioTech
ChemiDoc™ MP System Biorad
CO2 incubator CB210 Binder, Tuttlingen, Germany
Eclipse 80i light microscope Nikon, Langen, Germany 
Lab scale
Kern, Balingen-Frommern, 
Germany
Magnetic stirrer VWR, Darmstadt, Germany 
Microcerntrifuge 5415D
Eppendorf, Hamburg, 
Germany
pH-Meter MP 220
Mettler Toledo, Gießen, 
Germany 
pH Meter Accu Jet® pro, Brand
PowerPac Universal Power Supply
Bio-Rad Laboratories, 
Richmond CA, USA
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precision balance
Satorius, Göttingen, 
Germany 
Tecan M200 Multimode Reader Tecan, Crailsheim, Germany
Speed Vac RC 1010 UVP, Upland CA, USA
1D-SDS PAGE System
Mini PROTEAN TetraCell 
Bio-Rad
Autoclave Systec
37°C Incubator Binder
Ice machine Amersham Biosciences
ELISA-Washer
Biotrak II Washer 4 
Amersham Biosciences
ELISA reader
Multiscan EX 355 Thermo 
Electron Corporation
Heating block MKR 13 HLC
-80°C freezer Grant Instrumental Ltd
-20°C freezer Sanyo
4°C refrigerator Sanyo
Nanodrop TS100 Nikon Eclipse
Pipettes, in the range 0,1 µL-1000 µL
ND-1000 PEQLab 
Biotechnologie GmbH
Pipettes 5 mL, 10 mL, 25 mL Eppendorf
Pippetor Greiner Bio-one
shaker Unimax 1010 Heidolph
vortex KS12 Thermo scientific
Water bath Sartorius
centrifuges
Biofuge stratos, 
ThermoScientific – 16DH, 
VWR Galaxy
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4. Experimental procedures: In Vitro
In order to perform the in vitro part of the study, astrocytes, microglia
and neurons were isolated from either embryonic or 3 to 5 days old mice
pups. The cell types were confirmed using FACS analysis. The cell cultures
were  stimulated  with  proper  concentrations  of  STZ  and  different  ISO-1
concentrations. Supernatant of the samples were used for ELISA, Western
Blot and Nitric oxide assay. The cell lysate was used to extract the mRNA as
well as protein to perform ELISA, PCR and Western blot.
4.1. Isolation of mouse embryonic Astrocytes and neurons
These cell cultures were prepared to study the properties of individual
cell  types.  Fetuses  were  isolated  from  pregnant  mouse  (late  pregnancy),
lower abdomen was sprayed with 70% EtOH and cut medially through the
skin and muscles with a pair of scissors in order to expose the uterus and
embryos.  Fetuses  were  removed  and  placed  in  a  sterile  100-mm  dish
containing  an  excess  of  cold  L  15  medium.  Embryos  were  rinsed  and
transferred to the second 100 mm dish containing dissecting medium.
The  hindbrain  (containting  astrocytes)  and  forebrain  (or  cortex,  containing
neurons) were separated. Dura matter and blood vessel were removed from
the brain and samples were transferred to a 15ml Falcone and centrifuged to
remove the media. In order to detach the cells from each other, accutase was
added to the samples, followed by incubation at  36°C water-bath for 5 min.
samples were filtered using a 40µM strainer to remove the larger cells and
DMEM was added to stop the accutase activity followed by cetrifugation and
removing of the media. 
Proper  media  were  added  to  each  sample  (Neuroblastoma  and  DMEM
respectively  for  neurons  and  Astrocytes).  Number  of  the  cells  were
determined. Proper amount of cells were transferred to plates and incubated
in 37°C for further use.
Alternatively glia cells were isolated from 3 to 5 day old mouse pups using
CD11b  Microbeads  (Microglia)  or  ACSA-1  Microbead  kit  (for  astrocytes)
following company's instructions.
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The cells were sub-cultured regularly to refresh nutrients in the media. The
cultured  were  trypsinz  d  once  cells  reached  the  proper  confluence  and
passaged into new  dishes  containing  fresh  media  and  were incubated  at
37°C, in 7.4% CO2
 
4.2. FACS staining of microglia and astrocytes
Flueroscence-activated cell sorting (FACS) was performed to confirm
that the isolated and sorted cells from mouse pups and fetuses were indeed
the types of the cells that we aimed for. Aliquots of samples were prepared
containing  at  least  2  x  105  cells  in  each  tubes.  Microglial  samples  were
blocked using Fc block (anti-CD16/CD32) and CD11b-FTIC was used to label
these cells. 
ACSA-PE was used as the marker to  label  the astrocytes.  Samples were
analyzed immediately or went through a fixing protocol for later use.
4.3. Activation of cultured cells with STZ
A total amount of 106 cells were added to each well of a 6 well culture
plate.  (using  Fuchs  Rosenthal  Counting  Chamber)  and  were  incubated
overnight at 37°C, 7.4% CO2. Proper concentrations of ISO-1 were added to
appropriate  wells  1  hour  prior  to  stimulation,  followed  by  delayed
administration  of  STZ  (after  one  hour)  with  the  purpose  of  avoiding
interactions between ISO.1 and STZ.
4.4. Cell proliferation assay XTT
XTT was used to measure viability of the our different cell  types to
external factors (ISO-1 and STZ). The experiment was performed in 96 well
plates over 3 days.
On the first day, cells were passaged and diluted the to 30,000 cells per well
which  was  incubated  overnight  at  37°C,  7.4%  CO2.  On  the  second  day,
proper concentraions of staurosporin was added to the cells. Staurosporin is
a kinase inhibitor  that  induces cellular apoptosis.  Other wells were treated
with  different  concentrations  of  ISO-1  or  STZ  and  plates  were  incubated
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overnight.  On  the  third  day,the  working  reagent  and  XTT activators  were
prepared  and  the  experiment  was  performed  based  on  the  manufacturs
protocol (  cell  signaling technology;  #9095).  The plates were evaluated by
defining the absorbency at 490nm (or 450nm), with a reference wavelength of
630-690 nm (to correct for fingerprints, smudges) in order to define the toxic
levels for different chemical compounds used for the experiements.
4.5. Nitrite measurement (Griess reaction)
This  procedure was  performed in  order  to  measure  the amount  of
nirite as one of the primary products of the NO breakdown. The samples were
com paired to an standard series, which is prepared in phosphate buffered
saline  (PBS)  without  Ca  or  Mg  (PBSdef  was  used  as  blank).  1%
Sulfanilamide Solution (in 5% phosphoric acid) was added to all experimental
samples  and  wells  containing  the  dilution  series  for  the  Nitrite  Standard
reference  curve  and  the  plate  was  incubated  for  5  minutes  at  the  room
temperature.  50μl  of  the  0.1%  NED  (0.1  %  N-1-naphtylethylendiamin-
dihydrochloride in ddH2O) Solution was added to all wells followed by another
5 minutes of  incubation while protected from light.  A purple/magenta color
was formed and the absorbance of the plate was measured immediately at
550nm .
4.6. Cell lysis and protein extraction
In  the  Radio-immunopercipitation  Assay  (RIPA)  lysis  of  monolayer-
cultured  mammalian  cells,  the  RIPA Buffer  was  used  to  lyse  mammalian
cells,enabling extraction of proteins from cytoplasm, membrane and nucleus,
without degrading them. Protease inhibitor was added to buffer before using
(Complete  Protease  Inhibitor  Cocktail  Tablets).  The  culture  media  was
removed and the cells were washed gently by adding 1x cold PBS to remove
the  residual  media  and  dead  cells.  RIPA buffer  was  added  to  the  plate
followed by 5 min incubation on ice. Cells were scraped and transferred into a
15mL falcon tube and centrifuged at 14000 x g for 15 min. Supernatant was
discarded at the pellete was stored at -20°C for further investigations. In the
case of Tissue samples, Tissue Protein Extraction Reagent (TPER) was used
instead of RIPA to extract the protein. The cells were homogenized in TPER
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and then centrifuged to remove the cell debris. Samples were stored at -20°C.
4.7. Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to measure the secretion of different cytokines from
primary  cell  cultures  of  mouse  glial  or  neural  cells  treated  with  different
concentrations of  STZ and ISO-1.  Media was collected for  each well  and
centrifuged for 5 min with 13.000rpm to remove the dead cell  bodies. The
supernatant  of  this  step were transferred to new 1.5ml tubes and 50µl  of
Protease inhibitor  (20x)  was added to the samples.  Tubes were stored at
-20°C or used directly.
High binding ELISA plates were coated with proper concentrations of primary
antibody solved in PBS and stored at 4°C overnight. Plated were “blocked” on
the following day using 100µl reagent diluent (1% BSA in PBS pH 7.4). 
Standard  curves  for  cytokine  of  interest  was  generated  using  purified
recombinant  proteins  provided  by  the  kit  and  the  assay  was  performed
according to manufacturer’s instructions. Absorbance was measured at 450
nm to 650 nm using SpextraMax Plus 384 microplate spectrophotometer. The
cytokines were normally measured in the spectrum of 10 to 1000 pg/ml. 
The  represented  results  reflect  (at  least)  three  separate  measurements
obtained from different cell cultures on different days. 
4.8. Isolation of total RNA: 
The  mRNA  was  extracted  from  confluent  monolayers  of  primary
cultures of mouse glia cells or neurons using Piotr Chomczynski and Nicoletta
Sacchi protocol. The concentration of RNA in each sample was quantified by
measuring absorbance at 260 nm using spectrophotometer.
4.9. Synthesis of cDNA: 
Synthesis  of  complementary  DNA (cDNA)  was  performed  prior  to
qPCR,  in  order  to  synthetize  DNA  from  mRNA,  using  cDNA  Reverse
Transcriptase Kit following manufacturer's structure. Proper primer pairs were
designed using ncbi library and PCR was performed using 
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4.10. BCA protein assay: 
Bicinchoninic  acid  assay,  also  called  Smith  assay,  is  a  test  for
detecting andquantifying the amount of proteins. Protein causes reduction of
Cu2+ to Cu1+ ion in an alkaline solution; bicinchoninic acid (BCA) reacts with
the reduced ion to form violet coordination complexes. The intensity of the
color  and  hence  the  absorption  at  562nm  is  directly  proportional  to  the
amount of protein present in the sample. Bovine serum albumin (BSA) is used
to  create  a  standard  series.  The  experiment  was  performed  based  on
manufactures protocol. Absorbence of the samples were measured at 560 nm
to define the concentration of the protocol in each sample
4.11. Western blot:
50µg  of  total  protein  measured  by  BSA  assay,  was  separated
according to their molecular weight by 12% SDS-PAGE polyacrilamide gels .
Molecular weight marker is loaded into the first lane. 
The separated proteins were transferred to Immobilon-P PVDF (Millipore) or
nitrocellulose membranes using a semi-dry transfer apparatus with a current
density of 1 mA / cm2 for 2 hours, following by an overnight blocking step at
4°C.  Proper  detection  antibody  (BAF289  Human  MIF  Biotinylated  Affinity
Purified PAb, Goat IgG) was used for detection of the protein. Horseradish
peroxidase (HRP)-conjugated streptavidin secondary antibody was used to
visualized  and  identify  target  proteins  according  to  the  manufacturer’s
recommended protocol. Pierce ECL western blotting substrate was used to
detect HRP activity in the samples and the images were aquired in ChemiDoc
MP system device.
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4.Experimental procedures: In Vivo
Following  in vitro  studies to show the inflammatory potential of STZ
molecule  in  primary  brain  cell  cultures,  we  decided  to  test  whether  local
inflammation induced by ICV administration of STZ in the hippocampus of
wild type (C57BL/6) and MIF-KO mice can induce the expression of cytokines
in  vivo as  well,  and  if  this  inflammatory  response  leads  to  impairment  in
learning and memory in animals.
Different groups of animals tested included:
1. Untreated control
2. Vehicle ICV injected (Veh-ICV)
3. STZ ICV injected (STZ-ICV)
4. STZ-ICV + ISO-1 treatment: the purpose of this group is to determine
the  effects  of  MIF  inhibition  in  downregulating  the  inflammatory
cytokines and possible effects  on spatial  and reference memory in
C57BL/6 mice
5. MIF-KO Veh-ICV
6. MIF-KO STZ-ICV
All animals were tested by Rotorad and open-field task to show the
loco-motor  capability  among  different  study  groups.  As  mentioned  before
Streptozotocin (STZ) is a fungal antibiotic which was originally used for rodent
model of  diabetes mellitus (200mg/kg intraperitoneal; Like & Rossini 1973).
This substance is  also a clinically approved drug for  late-stage pancreatic
cancer under the name of zanosar. For the purpose of our experiments we
also  used  Zanosar,  injected  intracerebroventricularly  (3mg/kg,  ICV-STZ).
Different groups were tested for spatial and context memory 6 weeks after
operation using clockmaze and classical, fear conditioing. 
The animals were sacrificed after  this  step and sample were prepared for
immunohistochemistery and qPCR analysis (Fig. 4.1.)
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Figure 4.1. flow chart for in-vivo experimental design:
the in vivo experiments were performed on wild type and MIF-KO animals, both
being ICV injected with STZ molecule. STZ-ICV group of wild type was divided
into two groups being treated either with and MIF inhibitor (ISO-1) or Vehicle. 
Animal  were  tested  for  hippocampal  dependent  spatial  memory  (spatial,
contextual) and after sacrificing different experiments (immunohistochemistery
and qPCR) were performed to analyze the samples.
4.12. Animals:
Male C57BL/6 animals were obtained from the Jackson Laboratory,
USA. The MIF-KO strain was provided by the Feinstein Institute for Medical
Research (FIMR). Animals were caged with  ad libitum access to food and
water,  maximum 5 mice per cage in a controlled environment on 12 hour
Light-Dark cycle (lights on 9 am). All animals were handled to reduce anxiety
before starting the experiments. All experiments were carried out during the
dark period and in a noise controlled room, in accordance with regulations in
FIMR  and  US  ethics  rules.  The  ICV-STZ  model  of  dementia  and
neurodegeneration  has  been  used  to  study  molecular  and  behavioral
changes  due  to  inhibition  of  MIF,  as  well  as  in  vitro cultures  of  neurons,
astrocytes and microglia.
4.13. Rotarod
Rotarod task was performed to monitor  the motor coordination and
learning in mice. The mouse was placed on a rotating rod and the latency to
fall from this apparatus was measured. Animals normally fall very quickly in
the first  trials  but  over  the  trials  the  duration  increases  in  normal  healthy
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animals.  Motor  learning  was  assessed  by  making  a  comparison  between
latencies in different treatment groups. The velocity of the rotating rod was
increased by 0.5 cm/sec. every 5 sec and the mice was tested for 4-6 trials.
Mean latency to fall in different trials was used for plotting the data.
4.14. Open field
In this task the exploration behavior and the anxiety level in animals
were measured. As a normal behavior mice are hesitant to stand in the center
and they only explore this area once in the while. The apparatus is a white
box measured 72 x 72 cm with 36 cm walls. A central square is draw in the
original  box,  and  measure  the  duration  the  mouse  spends  in  the  center
square as well as the distance the animal has walked during the experiment.
The task was performed in dark room with background light, the mice was
placed in the box for 5min and the behavior was recorded via a camera. 
Figure 4.2. Rotarod apparatus
Rota-rod is a basic experiment performed to evaluate the motor coordination in 
rodent.
Source:
https://www.mouseclinic.de/screens/neurology/technologies/index.html
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4.15. Rodent stereotaxic surgery
This type of surgery is used to access a precise location in the brain,
based on the idea that the features on the skull can indicate the position of
different structures in the brain. In fact,  the bregma is the point where the
sagittal and coronal sutures joins the parietal and frontal bones, and is used
as the “stereotaxic zero point”. From this point, the hippocampus is localized
for  injection  of  STZ  or  vehicle,  to  create  a  mouse  model  for
neurodegenerative driven dementia. 
The  animal  weight  was  measured  to  decide  the  amount  of  anesthetics
(isoflurane,  an inhalatory anesthetic  1.5% v/v  supplemented with  oxygen.)
animal was placed in a stereotaxic head holder (David Kopf, Tununga, CA,
USA).  The  head  was  scrubbed  with  ethanol,  on  the  top  if  the  head.  An
incision was made in the brain from posterior to anterior. The bregma was
used as stereotactic zero point,  stereotaxic  coordinates used to target  the
Figure 4.3. schematic presentation of open field apparatus, 
EthoVision®XT software is used to analyze the data, latency in center zone and
near walls area are measured and plotted. Below are the representative images
showing  different  behavior  in  the  open  field.  While  representing  the  normal
behavior  mice  spent  most  of  the  time  close  to  walls.  In  unusual  conditions
however (for example neophobia; one of the characteristics in APP mice), animal
tends to stay within the center of the cage (Down right).
Source: https://mazeengineers.com/tag/mouse-behavior/ 
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hippocampus for toxin delivery are: x, +1.0, y -0.3. Drill a hole in that position,
avoiding drilling too deep. The Hamilton syringe (Hamilton 80100, 1ul, 26G) is
filled  with  either  STZ or  Vehicle  and  the  needle  is  re-positioned  to  be at
stereotaxic zero point, and then to injection position x y z coordinates of (+1.0,
-0.3, 0). And then slowly to target z: -2.6. Volume of 3 ul of toxin or vehicle
was injected very slowly and at least 10 min is given for the drug to diffuse
after injection. The needle was pulled slowly up, a small amount of surgical
glue was used to close the cut down. As post surgical care, the animal was
injected with buprenorphine and placed on a heat pad for recovery.
4.16. Clockmaze
The clockmaze  apparatus  is  made of  a  transparent  circular  plastic
pool with 12 possible exits. Different masks are placed around the maze as
cues to assist formation of the spatial memory and the position of the objects
remains unchanged throughout the experiment. 
Water  was  added  to  the  maze,  up  to  2  cm  deep  (shallow  water),  the
temperature was reduced to create a stimulus for escape motivation from the
maze. Cages were transferred to the experimental room, drapes were used to
block the view of the maze and also the animal being tested cannot see the
experimenter during the trials. A video camera was placed directly above the
pool and connected to a PC running Ethovision Software. The area of the
maze  was  defined  and  the  12  exits  were  defined  as  sub-zones  in  the
program. The tracking started automatically as the animal was placed in the
maze (based on the contrast between the mouse and the background). 
The procedure can be broken down into following parts
A.  Black Corridor,  the study started in  the black corridor  (a separate light
protected chamber) where the animal learned to use the tube exit as
escape from water (4 trials on day1). The cut-off for these trials was 30
sec.
B. White corridor:  a transparent  chamber placed inside the clockmaze, for
visual training, and to teach animal to escape from the maze via a tube
(4 trials on day2) 
C. The clockmaze had 11 closed exits and only one correct path to exit the
maze. The animal was placed in the middle of the maze facing the tube
opposite  the  exit  (facing  tube  6,  if  the  exit  is  tube  12).  Training
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consisted of 12 trials in 3 successive days, with maximum length of 60
seconds per trial. In case of failure in finding the proper exit, the animal
was manually guided towards the exit. Mice were placed under heating
lamp for recovery to avoid hyperthermia. Parameters measured in this
task include:
a.  Latency and  path  length:  the  time  and  distance  that  the  animal
requires to find the exit.
b. Errors: defined as trying to enter the wrong exit
c. Strategy: they are based on the number of the errors and the latency,
and defined as follows:
(c.1) Spatial: when the animal exits the maze with 3 or less errors.
(c.2) Chain: when the animal tries more than 3 decoys to find the
open escape, thus number of errors is >3.
(c.3) Futile: when the animal fails to find the exit within 60 sec.
Passing by the real exit without entry frequently happened in early trials but if
the  animal  did  not  show  improvement,  it  was  considered  as  a  sign  of
impairment in spatial cognition.
D. Probe trial: in this trial the exit tube was blocked. We measured the time
the animal spends in front of the escape exit, as an indicator for the
usage of extra-maze cues and reference memory.
E. Reverse trial (or spatial reversal): the exit was relocated to the opposite
tunnel and animal was tested for another set of 12 trials over 3 days.
Figure 4.4. Clock maze; the round arena is surrounded by 12 exits, only one of
them is  an escape to  the maze (represented in  green arrow).  The mouse is
placed to face the opposite exit (the red arrow) and is given one minute to solve
the task.
Jove: journal of visualized experiments: www.jove.com 
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4.17. Fear conditioning
In  Fear  conditioning  paradigm,  a  neutral  conditional  stimulus  (CS),
such  as  a  pure  tone  (10  sec,  80  dB),  occurs  in  conjunction  with  an
unconditioned  stimulus  (US),  such  as  a  foot-shock  (1  sec,  0.5  mA).  The
animals  learn  to  quickly  associate  the  CS  with  the  US  and  display  a
conditional response, such as freezing when presented with the CS alone.
Therefore  we  measure  the  duration  of  freezing,  which  is  described  as  a
complete absence of movement except for respiration, as is the index for fear
memory. 
The apparatus was cleaned before starting each trial to avoid an olfactory
context. All trials were recorded for further analysis.
The amount of freezing and the presentation of CS and US was controlled by
software (FreezeFrame). This experiment was conducted over the period of 4
days:
Day1, Habituation: the animal was familiarized to the fear-conditioning (FC)
chamber for 10 min.
Day2, Fear conditioning: the animal learned to associate the US with the CS.
Mice were given 5 presentations of the CS, which co-terminates with the US.
Day3-,  Context  memory:  the  mice  returned  to  the  test  apparatus  and
observed for 10 min.
Day4-Tone Memory: the animal was placed in a differently shaped chamber
and is exposed to the auditory cue alone.
Figure 4.5. Fear conditioning apparatus: 
The red arrow represents where the mouse is placed, the camera placed on the
top allows recording and analysis of the animals movement in terms of activity to
immobility ratio (fear conditioning).
Where the mouse 
is placed
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4.20. Immunohistochemistry
After  sacrificing  the  animals,  the  brains  were  excised  and  fixed  in
Paraformaldehyde (PFA, 4% PFA, bufferd with PBS) overnight  at 4°C and
then  transferred  into  30%  glucose  with  azide  for  long-time  storage.  The
samples  were  cut  at  the  thickness  of  50  m  slices  (cryosections)  and
incubated in 3% H2O2 in PBS to remove endogenous peroxidase, which may
create  non-specific  background  after  HRP conjugate  application.  Samples
were blocked with  5% milk  in  PBS for  1h at  RT and transferred to  wells
containing first antibody at proper concentration, and incubated overnight at
4°C. Secondary antibody was applied on the following day to the samples at
RT for 2h. Samples were transferred to HRP conjugate solution for 1h at RT.
Brain sections were visualized using 3,3’-diaminobenzidine (DAB). and 0.3%
H2O2 was used to stop the visualization reaction. Samples were transferred
to  glass  slides  and  dehydrated  using  80%,  95%,  100%  ethanol.  Finally
paramount was used to fix the slides. The slides were left overnight under the
hood to complete drying and fixation and analyzed under the microscope.
4.21. qPCR
The hippocampus of the animal was stored in 200µl TRIZOL realgent
(Invitrogen)  for  the purpose of  RNA isolation.  50µl  1-Bomo-3-chloropropan
(BCP) was added to the samples and the mRNA was isolated using QiAgen
mRNA isolation kit (Rneasy mini-kit). The  cDNA was prepared as described
previously. The primers for this purpose were designed based on accession
number from a library of  primers for  SYBR green and were ordered from
Fisher  Scientific.  Quantitative  PCR  (qPCR)  was  performed  using  SYBR
Green  Master  Mix  (SIGMA-ALDRICH).  The quantity  of  target  genes  were
normalized  to  house  keeping  gene  of  choice  (Beta-actin)  using  the
comparative  Treshhold  Cycle  (CT)  method  (ΔΔCT).  In  this  method,  the
average of the Ct values for the house-keeping gene and the target genes of
interest are compared in the experimental and control conditions, returning 4
different values. ΔΔCT is calculated by subtracting differences between target
and housekeeping values under control condition from differences between
target and housekeeping values under experimental conditions. Value of 2^
ΔΔCT  is  calculated  to  get  the  expression  fold  change.  Results  were
expressed as mean ± standard error of the mean (SE) of at least four different
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animals per each experimental group.
4.22. Statistical analysis
All graphs were prepared using either ggplot2 package (R program) or
excel. Data are expressed as  means ± Standard Error of the Mean (SEM).
Statistical  analysis  was  performed using  dplyr  packages  in  R program or
excel. For the clock maze and fear conditioning, the daily performance of the
treatment groups was analyzed using One or Two-way ANOVA followed by
unpaired student T test or Bonferroni`s post test. Unpaired student t test was
performed on ELISA results to test the null  hypothesis and Mann–Whitney
test was used to asses differential expression on qPCR data. 
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5. Results
5.1. Characterization of the anti-inflammatory effect of MIF inhibition on
glial cells undergoing STZ-induced inflammation
In the first part of this study we investigated the effect of MIF inhibition
on cytokine production in glial and neural murine cultures  in vitro.  STZ was
used to stimulate  the microglia  astrocytes  or  neurons in  vitro. Release of
different  cytokines was measured in transcriptional and translational levels
both with or without MIF inhibition in order to elucidate the role of MIF as the
early cytokine in regulating the expression of other mediators of inflammation.
5.1.1.  MIF  protein  is  released  in  response  to  STZ  stimulation  by
microglia and astrocytes:
In a pilot study, MIF production was measured using ELISA kit to show
that this cytokine was released in response to STZ stimulation of astrocytes
and microglia. Intracellular MIF was detected by Western blotting, as well as
PCR, to show mRNA expression levels of this protein within the cell (data not
shown). We used primary cell cultures of astrocytes and microglia, isolated
from  postnatal  C57BL/6  mice,  for  stimulation  with  1mM  and  0.5mM  STZ
(respectively for astrocytes and microglia). ELISA was used to test cell culture
supernatants, after 24 h, for MIF release (Fig.5.1). We observed a baseline
level for MIF release from the cells in both astrocytes and microglial cells (150
pg/ml).  Unlike  most  cytokines,  MIF  is  not  produced  de  novo in  an  early
response to a stimulus. It has been previously shown that upregulation in the
mRNA levels of MIF is a delayed response (Lanahan et al. 1992) and that
MIF is pre-stored intracellularly, which allow for its release as an early-phase
cytokine (Atsumi et al. 2007).  In the next step, we isolated the intracellular
mRNA which was used for  cDNA transcription  followed by a PCR.  In the
visualization  on  the  agarose  gel  we  observed  no  influence  on  mRNA
expression levels after STZ stimulation.  It might be possible that to see an
increase in the mRNA level of MIF, we should look for time points later than
24  hours.  We  observed  that  the  use  of  different  concentrations  of  MIF
inhibitor,  ISO-1,  does  not  affect  the  extracellular  secretion  levels  of  the
protein,which is consistent with the finding that ISO-1 blocks the tautomerase
active site of MIF molecule, without affecting the amount of the protein itself
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(Al-Abed et al. 2005). MIF protein was released in both cell types in response
to STZ molecule
Figure 5.1. Extra and intracellular MIF, in response to STZ stimulation,
A and B: Significant increase in MIF secretion in supernatant of the astrocytes (A)
and microglia  cells  (B)  in response to  STZ stimulation after  24h measured by
ELISA . Graph represent the mean of three biological replicates, bars represent
standard errors of the mean(± SEM), (*P < 0.05, unpaired Student's t test)
C. Analysis of PCR products on agarose gel, the polymerase chain reaction (PCR)
was performed using samples collected from astrocytes, reflecting the intracellular
mRNA expression levels for MIF and D-DT genes, the expression in mRNA level
remained unaffected in comparison to housekeeping gene after STZ stimulation.
Similar results were observed with microglial samples (data not shown)
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5.1.2. Application of ISO-1 does not affect the secretion of MIF
Following the observation that MIF is released in response to STZ, we
applied the well-established MIF inhibitor ISO-1 in order to find out if the STZ
dependent  release  of  MIF  can  be  blocked.  ISO-1  was  used  at  final
concentrations of 25, 50 and 100 µM to the cell culture one hour prior to STZ
stimulation,  and  the  supernatant  was  tested  after  24  hours  for  the
concentration of MIF molecule. Based on our observation, ISO-1 does not
affect the extracellular amount of the MIF molecule.
5.1.3. STZ stimulation induces IL-1beta and IL-6 protein and mRNA
IL-1 is  a  member  of  IL-1  superfamily  of   cytokines  (Maldonado,
Andrian 2010) and one of the major neuroinflammatory signals (Drake et al.
2011) released from microglia and specially astrocytes in the  hippocampus,
where  it  plays  a  dual  role  in  either  supporting  hippocampal-dependent
memory  (Pearson-Leary et al. 2015), or impairing the memory (Ross et al.
2003). Astrocytes seem to be the main source of IL-1 in the CNS (Wen Yin
Wang et al. 2015).Using primary microglia and astrocytes, we assayed for IL-
1 and IL-6 cytokine production, at mRNA (PCR) and protein levels (ELISA;
Fig.5.2). MIF-KO cells exhibit decreased type 1 IL-1R expression (Toh et al.
2006), indicating that inhibition of the MIF can lead to down regulation of IL-
1 secretion from the cells. In our experiment, extracellular IL-1 protein was 
significantly  and  dose  dependently  inhibited  by  blocking  the MIF’s  activity
even at the lowest concentration of ISO-1 (A and B). 
IL-6 is classically known to be  a pro-inflammatorycytokine and a marker for
systemic  activation,  which  is  shown  to  have  also  regenerative  activity
(Scheller  etal.2011).  MIF regulated IL-6 cytokine expression by influencing
NF-kβ (Chuang et al. 2010). Apart from being one of the major cytokines, IL-6
in the brain plays both neuroprotective and neurotropic roles (Quintana et al.
2013). Although astrocytes are known to be the main source of this cytokine
(van Wagoner et al. 1999; Quintana et al. 2013), microglial expression of IL-6
increases dramatically in the brain of aged mice (Van Wagoner et al,. 1999),
which is associated with cognitive decline. IL-6 was increased in response to
STZ treatment; this expression was attenuated while MIF was inhibited (Fig.
5-2 C and D).  Interestingly MIF inhibition at  highest  concentration (100µM
ISO-1) leads to suffocation in release of these cytokines in mixed glial culture
(astrocytes to microglia ratio, 1:5 – Data not shown). 
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Figure 5.2. MIF-mediated expression of IL-6 and IL-1ß from astrocytes and
microglia, inhibitory effect of MIF suppression. 
ELISA results are plotted in graphs, Data are representative of three independent
biological replicates, error bars represents ± SEM (*P < 0.05, unpaired Student's t
test).
A. B. C. & D. TOP:  IL-1ß and ELISA assay results for  supernatant  of  murine
astrocytes and microglia after 24h STZ stimulation (red bar), both cytokine were
released in response to STZ stimulation in Microglia and astrocytes Using different
concentrations of  ISO-1 to inhibit  the MIF molecule (yellow, orange and brown
representing 25, 50 and 100µM of ISO-1 respectively) resulted in dose dependent
decrease in cytokine release in both cell types.
A.  B.  C.  &  D.  Bottom:  PCR  showing  the  mRNA  expression  level  of
proinflammatory cytokines interleukin-6 and interleukin-1β. IL-1β was strongly and
dose dependently in transcriptional level  after MIF inhibition. Similar effect was
seen in a lesser degree in the case of IL-6 .
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5.1.4. IL-10 is expressed by microglia in response to STZ:
It is known that STZ can induce release of anti-inflammatory mediators
(Naxin  Sun,  et  al.  2005),  to  investigate  this  statement  in  our  model,  we
investigated  presence  of  IL-10  as  an  anti-inflammatory  cytokine  in
transcriptional and translational levels.
IL-10 is  one of  the anti-inflammatory cytokines that  is  elevated during the
course of chronic inflammation in the brain (Strle et al. 2001), for the purpose
of  promoting  the  survival  of  the  neurons  (Jia  et  al.  2009).  It inhibits  the
production of pro-inflammatory cytokines from astrocytes and is known to be
produced  in  different  brain  regions  such  as  neural  tissue,  pituitary  and
hippocampus,  where  it  induces  a  specific  activated  microglial  phenotype
concomitant  with  changes  in  hippocampal  Long  term  potentiation  (LTP)
responses  (Almolda  et  al.  2015).  IL-10  is  decreased  by  aging  (Frank,
Barrientos, et al. 2006), which leads to priming of microglia and increased IL-
1 expression (Hermes et al., 2008). Based on our observations STZ caused
1.5  fold  induction  of  anti-inflammatory  IL-10  in  microglia,  which  remained
unaffected  as  MIF  was  blocked,even  at  highest  concentration  (100  µM)
(Fig.5.3).  It  has  previously  been  ascertained  that  the  absence  of  MIF
enhances IL-10 production  in vivo  (Madeira et al.  2012) and that MIF can
down regulate IL-10 expression (Sashinami et al. 2006 ). IL-1 expression is
down regulated by IL-10 (Heyen, JR et al. 2000). The synchronized presence
of IL-10 and blockade of  MIF can clarify the strong IL-1  inhibition in the
lowest applied concentration of ISO-1 (25µM). Furthermore IL-10 is known to
hinder  synthesis  of  MIF  and  subsequently  the  NO released  by  MIF  (MIF
dependent nitric oxide synthase- Kerschbaumer et al. 2012).
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5.1.5. TNF-alpha is released by microglia in response to STZ
TNF-  contributes to the pathogenesis of neurodegenerative  diseases
(Buko et al. 2015) and has a diverse range of functions in the CNS. TNF-
release in hippocampus results in excitotoxic neuronal damage (Bock F et al.
1996), and the induction of ICAM-1 on human fetal  astrocytes  (Zhou et al.
2016). Astrocytes express TNFR1 high affinity receptors for  TNF- . In our
experiments,  protein  and  mRNA levels  of  TNF-  in  astrocytes  were  not
affected  by  STZ  stimulation,  leading  to  the  assumption  that  maybe  the
astrocytes react to STZ stimulation by upregulating the receptor for TNF-
and not the cytokine itself, however we did not look for the TNFR1 expression
Figure 5.3. in vitro effect of STZ stimulation on IL-10 expression in protein
and mRNA level in microglia cells.
TOP: IL-10 ELISA results plotted in graphs,  representative of three independent
biological replicates, error bars represents ± SEM of triplicate technical replicates.
Murine microglia supernatant was checked after 24h of STZ stimulation (red bar),
with  or  without  ISO-1  inhibition  MIF  molecule  (yellow,  orange  and  brown
representing 25,  50 and 100µM of  ISO-1 respectively).  IL-10 was significantly
released in response to STZ stimulation in comparison to control (Grey bar, P <
0.01) and remained unaffected when MIF was inhibited.
Bottom: Representive agarose gel electrophoresis illustrating IL-10 PCR results,
inhibition of MIF didn't affect the STZ mediated IL-10 expression in transcriptional
level after 24h in microglia. 
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levels  in  the  astrocytes.  However  TNF-  was  released from astrocytes  in
response to LPS (data not shown). TNF-  was detectable extracellularly in
microglial culture  in vitro, 24 h after STZ stimulation (Fig.5.4.),  which may
suggest that microglia are among the primary sources of TNF-  production in
CNS  inflammatory  response.  ISO-1  treatment  effectively  suppressed  the
expression  of  this  cytokine  in  microglia  cultures,  yet  it  was  not  dose
dependent, which can be explained by fact that IL-6 can control the TNF-
expression as well.  Whereas MIF induces the production of TNF-α, IL-6 is
capable of down regulating its expression (Stenvinkel et al. 2005), meaning
that the concentration of TNF-  is not solely MIF dependent, as a result of
which MIF inhibition affects TNF- , but not in a dose dependent manner. 
Figure 5.4. TNF alpha expression in microglia 
TOP:TNF alpha  released  from microglia  cells  measured  by  ELISA after  24h
following stimulation with 0.5 mM STZ (red bar) and 25, 50 and 100 µM ISO-1
(respectively  yellow,  orange  and  brown  bars)  as  MIF  inhibitor.  Graph  is
representative of three independent biological replicates, error bars represents ±
SEM of triplicate technical replicates. (*P < 0.05, unpaired Student's t test).TNF
was released extracellularly 24h after STZ stimulation from microglia cells, and
was significantly reduced in response to 100 µM ISO-1.
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5.1.6. Astrocyte-specific induction of IL-12p40:
IL-12 is a pro-inflammatory cytokine that in bioactive form (IL-12p70) is
a heterodimer made of two subunits: IL-12p35 and IL-12p40. In regards to our
study,  these  two  subunits  are  regulated  differently  in  response  to  STZ
stimulation.  IL-12p40  is  also  capable  of  forming  a  homodimer,  IL-12p80,
which can induce the nitric oxide synthase in microglia via attachment to IL-
12R beta 1 receptor on microglial  cells (Jana M, et al,.  2009) and is also
found in multiple sclerosis lesions (Windhagen et al. 1996). We detected no
differences in mRNA and protein expression level for IL-12p35, IL-12p40 was
increased in response to STZ and diminished in mRNA transcript and protein
level in presence ISO-1 in astrocytes(Fig. 5.5.), we were unable to detect the
signal in microglia. 
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Figure 5.5. STZ mediated astrocytic IL-12-p40 production (ELISA) 
TOP: Effect of MIF inhibition on IL-12p40 release from astrocytes in response to
1mM STZ stimulation after 24h. Graph is representative of 3 biological replicates,
Data are expressed as the mean of 3 technical replicates ± SEM ( *P < 0.05 and
and **P ≤ 0.01, unpaired Student's t test)
Bottom:  cDNA after  24h from astrocytes  treated  with  1mM STZ analyzed  by
agarose gel electrophores. IL-12p40 was upregulated in transcriptional level after
24  hours,  which  was inhibited  with  Inhibition  of  MIF (at  highest  concentration
only). The mRNA level for IL-12p45 stayed unaffected throughout the experiment.
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5.1.7. Cytokine profile in MIF-KO astrocytes and microglia: 
Based  on  the  observation  that  inhibiting  MIF  leads  to  attenuated
cytokine response in glial cells after STZ stimulation, we hypothesized that
MIF-KO cells might exhibit a decreased response to STZ stimulation. To test
this  hypothesis,  MIF-KO  astrocytes  and  microglia  were  prepared  using
prenatal  mice  pups,  and  STZ  treatment  was  performed  with  the  same
protocol as WT cells, and the supernatants were tested after 24 hours (by
ELISA) for the regulation of different cytokines. 
5.1.8. MIF-KO cell cultures exhibit dampened IL-6 but not IL-1 beta 
response to STZ: 
We determined the expression level of IL-6 in these cells in response
to  STZ  stimulation.  No  significant  increase  was  detected  in  extracellular
amount of the IL-6 cytokine in MIF-KO astrocytes, even when we increased
the concentration of STZ to 2 mM. Also, we did not observe any increase in
TNF-  extracellular  protein level.  In contrast  to TNF-  and IL-6,  IL-1 was  
increased in MIF-KO astrocytes after 24 hours in response to STZ stimulation
(Fig. 5.6.).  This can be explained by considering the fact that IL-1 is pre-
stored in  the  cells  as  a precursor  protein,  and that  IL-1 can enhance its
production via a positive feedback loop (Jimbo et al. 2005).
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Figure 5.6. STZ induced IL-6 and IL-1 beta production, wt vs MIF-KO
ELISA results for IL-6 and IL-1 of MIF-KO astrocytes in comparison to the Wild
type  24h  after  STZ  stimulation,  Data  are  representative  of  three  independent
biological  replicates,  error  bars  represents  ±  SEM  of  triplicate  technical
replicates(**P < 0.01, unpaired Student's t test).
TOP: Differences in IL-6 production of MIF-KO cells vs. wild type cells, Whereas
IL-6 was produced in  a  dose-dependent  manner  in  wild  type  astrocytes  (blue
bars), no increase in extracellular IL-6 levels was observed after STZ treatment in
MIF-KO astrocytes (red bars)
Bottom: Comparison in respond to 1mM STZ between MIF KO and Wild type
astrocytes. No differences was observed in translational IL-1  levels between two
experimental groups (wt vs MIF-KO).
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5.1.9. Cytokines are produced in MIF-KO neurons in response to STZ
Neurons  in  the  hippocampus  regulate  many cognitive  behaviors  in
accordance with environmental and emotional cues, and like glial cells are
susceptible to inflammatory signals. Manipulations in the homeostasis of their
environment  can  lead  to  a  molecular  response  in  terms  of  production  of
inflammatory mediators as well as changes in cognition and behavior on a
larger scale. It has been shown that MIF is produced by the neurons in both
mRNA  and  protein  levels  (Nishino  et  al.  1995,  Bacher  et  al.  1998).
Hippocampal  neurons  from CA3 and  CA4 produce  MIF  protein  in  bovine
(Nishibori M, et al 1996) and rat neurons (Nishibori et al. 1996). MIF seems to
play an immune regulatory role in the CNS by being involved in degeneration
and regeneration of  the neurons (Koda et  al.  2004).  It  is  known that  STZ
stimulation in WT neurons leads to activation of ROS and cytokine discharge
into extracellular space. Here we tested the response in MIF-KO neurons to
STZ stimulation, by controlling the cytokine production (TNF- , IL-6, IL-1 ) 
after 24 hours of STZ stimulation. MIF-KO neurons were capable of producing
these  inflammatory  mediators  exposed  to  1mM  STZ.  We  observed
upregulation in  IL-6  and TNF- extracellular  protein  levels  (Fig.  5.7.).  this
seems  to  be  contradictory  to  the  findings  that  neuroinflammation  and
neurodegeneration is generally attenuated in MIF-KO mice (Leng et al. 2011),
then again it has been shown that affecting inflammatory hallmarks does not
happen during the first week after the insult (Inacio et al. 2011) so one might
argue that results based on examining the cytokine response after 24 hours,
and using in vitro techniques, is not completely accurate and that we should
examine the cytokine production in an  in vivo model.  Generally there is not
much known about IL-6 secretion in neurons, however it has been reported
that  membrane depolarization and excitatory amino acids can induce IL-6
production from neurons (Victoria Tarabin, et al 2002). 
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Figure  5.7.  Neuronal  expression  of  proinflammatory  cytokines  in  MIF-KO
cells in response to STZ stimulation
ELISA  results  for  IL-1 ,  TNF-alpha  and  IL-6  in  MIF-KO  neurons  after  24h
stimulation  using  1mM  STZ  represented  in  Red  bars  (Grey  bars  are  the
unstimulated control). Represented data is the mean of two independent biological
replicates ± SEM, each of which repeated in three technical replicates (*P < 0.05,
unpaired Student's t test).
A. unlike wild type neurons (Data not shown) no up regulation was observed in IL-
1  protein levels in supernatant 24h after stimulation.
B. and C. low basal levels of IL-6 and TNFa were slightly upregulated after STZ
stimulation.
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5.1.10. IL-6 production is upregulated by extracellular MIF: 
Stimulation of microglia with MIF (10 ng/ml) leads to TNF- and IL-6
production in these cells (Fig. 5.8.), indicating the possible role of this protein
in amplifying the cytokine response, possibly as an upsreatem modulator for
other inflammatory cytokines.
Figure 5.8. IL-6 production in response to MIF molecule,
ELISA results for  IL-6 production in response to stimulation with MIF molecule
(10 ng/ml) in wild type microglia cells.  Represented data is the mean of  two
independent  biological  replicates  ±  SEM,  each  of  which  repeated  in  three
technical replicates  (**P < 0.05, unpaired Student's t test). Using 10ng/ml MIF
molecule resulted in increase in IL-6 extracellular protein level
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5.2. Neuroinflammation as a risk factor for cognitive deficit
In earlier experiments we used STZ in vitro to show the inflammatory
potential of this molecule in primary brain cell cultures, during which the cells
reacted to stimulation by expression of a wide range of cytokines including IL-
6, IL-12p40, IL-1β and TNFa.
As the next step, we try to elucidate, whether systemic infection induced by
ICV administration of STZ in the hippocampus of WT mice (C57BL/6) induces
the  expression  of  the  above-mentioned  cytokines  in  vivo,  and  if  this
inflammatory  response  leads  to  impairment  in  learning  and  memory  in
animals.  Using  qpPCR,  we  measure  the  levels  of  key  cytokines  that  are
involved in learning and memory. We also aim to examine the inhibition of
MIF in ICV-STZ mice, suggesting the probable potential that inhibition of this
molecule can disrupt the neurogenesis process and affect the alteration of
learning and memory induced by neurogenesis.
Specific aims for this section includes:
 To assess the effects  of  ICV injection  of  STZ molecule  in  the
hippocampus  of  the  mice  in  terms  of  the  upregulation  of  the
different inflammatory cytokines and cognition deficits.
 To  assess  effects  of  inhibition  of  MIF  in  controlling  the
inflammation and improving the possible behavioral deficits.
 To investigate effects of the CNS chronic inflammation on weight
and  food  intake,  focusing  on  the  possible  role  of  MIF  in  this
processes.
Following approached was used to achieve these goals:
Male C57BL/6 mice were obtained from Jackon Labs. The different
groups  of  animals  tested  include:  [1]  Untreated  controls,  [2]  Vehicle  ICV
injection (Veh-ICV),  [3]  STZ ICV injection (STZ-ICV),  [4]  STZ-ICV + ISO-1
treatment. The purpose of group 4 is to determine the effects of MIF inhibition
in downregulating the inflammatory cytokines and possible effects on spatial
and reference memory in C57BL/6 mice, each group consists of 20 mice.
As mentioned before STZ is a fungal antibiotic that was originally used for
rodent model of diabetes mellitus (200mg/kg intraperitoneal; Like & Rossini
1973).  This  substance  is  also  a  clinically  approved  drug  for  late-stage
pancreatic  cancer  under  the  name  of  Zanosar.  For  the  purpose  of  our
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experiments  we  used  Zanosar,  injected  intracerebroventricularly  (3mg/kg,
ICV-STZ). It has been shown that ICV injection of STZ in the hippocampus is
followed by tissue damage and neurodegeneration in that area (Fig. 5. 9.)
One  of  the  main  cognitive  dysfunctions  to  arise  as  a  result  of
neuroinflammation in hippocampus is disruption of the spatial memory. We
decided to use a paradigm to assess the possible deficits in spatial memory
followed by assessments of the reference memory. Morris Water Maze is a
paradigm classically used to assess the hippocampal dependent behaviors
such  as  spatial  and  reference  memory.  However  the  MWM  is  originally
designed for rats that swim naturally in contrast to the mice that resent water.
In this project, animal were tested for their spatial memory, using clockmaze
which shares the similar theoretical basis with Morris Water Maze, however is
independent  of  anxiety  and  fear  component  (Fig.5.10.A),  it  omits  forced
swimming, which is one of the main stressors in the MWM task.All animals
were also handled before the experiments to reduce the anxiety level.  This
Figure 5.9. effects of STZ molecule on hippocamus, 
ICV injection of STZ in the hippocampus is followed by tissue damage and 
neurodegeneration in that area 
Kraska et al 2012
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memory assessment in this task is based on improvement in using the spatial
strategy,  reflecting  hippocampus  dependent  learning.  6  weeks  after  the
injections  animals  were  tested  for  their  hippocampal  dependent  spatial
memory  using  clockmaze  paradigm,  which  is  a  visuospatial  learning  task
modified  from Deacon & Rawlins 2002.  The following pattern (Fig.5.10.B)
represents the rational for the chosen strategies for each trial based on the
escape  path  and  latency.  The  selection  of  the  spatial  strategy  by  mice
indicates  a  normally  functioning  hippocampus.  Disruptions  in  the
hippocampus impair spatial learning and memory. 
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Figure 5.10. The clockmaze, a visuo-spatial learning task:
A. The apparatus is a water filled pool ( 80 cm diameter) with 12 exits ( represented
as 1 to 12 in circles)
 Only one exit is open,The arrow shows where the open exit is located (exit 11)
 the maze is surrounded by visual cues, to help developing contextual memories
( represented as A, B, C, and D)
 Water wets animals’ bellies, but animals can walk 
 Animals are placed in the center with back to exit  ( facing exit  4) and has 60
seconds per trial to solve the task (finding exit 11)
B. Different strategies to solve the task:
Strategies can be divided in following groups:
 1. Spatial: the most efficient, the animal immediately runs towards the exit by 
orienting to the extra-maze cues.
 2. Chaining or Sampling: is less efficient, the animal runs around the maze and 
checks every exit until they find the target.
 3. Futile: they fail to find the exit in 60 sec. 
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5.2.1. Behavioral screening:
Acute  inflammation  in  our  model  was  obtained  by
intracerebroventricular (ICV) STZ injection into hippocampus of the mice. In a
primary  screening,  the  mice  were  tested  for  muscle  and  spinal  function,
spino-cerebellar function, sensory function and autonomic function. The quick
screening allowed us to look for abnormal phenotypes, but we found that no
differences  exist  between  STZ-ICV  and  Veh-ICV  groups.  Moreover,  there
were no differences between groups in the open field test and the rotorad test
(Fig. 5.11.). 
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Figure 5.11. Primary muscle and spinal screening between STZ-ICV vs Veh-
ICV.
Open Field task and Rotarod were used to asses any probable differences in terms
of motor function between two experimental groups.
A. Traveled pathway differences between experimental groups in cm in Open field
arena (mean±SEM; Saline ICV, n = 20 and STZ- ICV, n = 20 – One way ANOVA).
No significant difference was observed. 
B. Different zones in Open field arena and amount of time mice spent in each zone
during the task. Data are represented as group means  ± SEM. The spent time in
different zones the arena were similar between STZ and Saline ICV group (Saline
ICV, n = 20 and STZ- ICV, n = 20 –one way ANOVA)
C. Motor coordination expressed as time period until falling off the apparatus over 5
trials. Dots represent average activity of animals in terms seconds for STZ-ICV (in
red, n=17) and Saline-ICV (in black, n=19) ± SEM for each group. Two-way ANOVA
with Bonferroni`s posttest was performed to assets the statistical significant. In both
groups, latency to fall  increases over the trials and no significant difference was
observed.
E f f e c t s  o f  M I F  o n  c h r o n i c  n e u r o i n f l a m m a t i o n 80 
5.2.2.  STZ-induced neuroinflammation impair  spatial  learning in adult
C57BL/6 mice: 
Spatial  memory  was  investigated  using  clockmaze.  Animals  were
given 4 trials per day for three successive days to locate the exit  tube by
using extra-maze cues. Untreated animals and the Vehicle ICV injected mice
exhibit similar performance in clockmaze (data not shown). Conversely, there
is  a  significant  difference  in  STZ-ICV  animals,  which  exhibit  problems  in
learning  the  task  (Fig.5.12.),  whereas  animals  with  normal  functioning
hippocampus are capable of finding the exit (using either spatial or sampling
strategy) after the first day.
The  learning  curve  represented  by  the  plot  for  the  percentage  of  spatial
strategy over trials (Fig.5.12.) shows almost effective learning in both groups,
but there is a significant difference in the rate of success. In the case of STZ-
ICV mice, the minor improvement in the learning curve for spatial strategy
does not  represent  a  successful  spatial  learning process.  The differences
between groups of mice in choosing different strategies can be studied even
closer by plotting the average number of errors made by each experimental
group over 12 trails. The higher rate of errors in STZ-ICV mice implies the
unsuccessful spatial learning in these animals, as they attempt to solve the
task by trying every possible exit as a result of failing to solve it spatially. As it
is obvious, STZ-ICV animals make significantly more errors in comparison to
Veh-ICV  animals  (Fig.5.13.),  indicating  the  incapability  of  this  group  to
remember the exit. Moreover, STZ-ICV mice are less successful in solving the
task than Veh-ICV animals (Fig.5.14.).
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Figure 5.12. Differences in preferred strategies by C57BL/6 mice
A. and B.  Percentage Stack bar chart  representing different  strategies used by
animals to escape the clockmaze over 12 trials (Black; futile, failure in solving the
task  within  one  minute,  white  represents  sampling  or  chaining  strategy,  where
animal  finds  the  open  exit  by  testing  every  tube  and  green  represent  Spatial
memory,  when  animal  knows  the  location  of  the  exit.  Data  is  represents  as
themean±SEM; Saline ICV n = 20 and STZ- ICV n = 20). Whereas the Spatial
memory is improved in Veh-ICV mice over 12 trials (A.), STZ-ICV animal showed
difficulties in improving the contextual memory, resulting in either relying mainly on
sampling strategy or failing the task (B.).
C. and D.  Average deploying of spatial  strategy in C57BL/6 mice Veh-ICV and
STZ-ICV. Spatial strategy significantly improves over 12 trials in Veh-ICV animals
(n=20, Spearman rho= 0.85, y = 0.0311x + 0.3977, R2=0.7485, P Value (two tailed
probability) = 0.000002). In contrast in STZ-ICV group, no changes were observed
(n=20 Spearman rho = 0.26, y = 0.0394x + 0.0606, R² = 0.6911, P Value (two tailed
probability)  = 0.26). Implying the disruption of contextual  memory as a result  of
STZ-ICV.
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Figure 5.13. Errors made by different experimental groups over 12 trials in
the clockmaze task
A. and B.  Average number of errors made by each group over 12 trials (Errors
defined average number of times animals tries a closed exit  to solve the task
(sampling  behavior).  A. The  amount  of  errors  made  by  Veh-ICV  animals
significantly decreased over 12 Trials (n=20, Student's T test),  B. whereas no
improvement was observed in STZ-ICV group (n=20)
C. plotted P value (two tailed Student T-test), comparing the differences in errors
made, between STZ-ICV and Veh-ICV over 12 Trials, red line represent P Value
0.05. Number of errors made significantly differs between test groups.
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Figure 5.14. Clockmaze Task; futile to non-futile ratio
The plot represent the ratio of non-Futile trials (where the task is solved using
either Spatial or Sampling strategies) in comparison to Futile (failure to solve the
task in 60 sec) in the last 4 trials between STZ-ICV (n=20) and Veh-ICV (n=20).
Veh-ICV animal solved the task significantly more successful in comparison to
STZ-ICV group (unpaired student's T test).
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Latency to finish the task is one of the primary measures that can be
analyzed  for  the  assessment  of  the  clockmaze  task.  All  animals  initially
require 60 sec or more to find the proper exit. In the clockmaze paradigm,
decrease in latency order to find the escape tube from the maze is considered
as a sign of acquisition of the task. Average latencies for untreated Vehicle
and STZ injected animals on successive days (Fig.5.15) show improvements
in performance for both STZ-ICV and Veh-ICV groups. Although the mean
latencies decrease over the 12 trials for both groups, for Veh-ICV animals
show a statistically significant decrease to find the correct exit (P value 0.01),
whereas the decrease is not significant for the STZ-ICV group.
After the first day, Veh-ICV animals mostly learn to move towards the exit in a
reliable manner represented by employing the spatial  strategy and shorter
latency time as  they repeat  the  task  in  the  following  trials.  In  contrast  to
vehicle-ICV animals, there was no significant improvement in terms of latency
and use of spatial strategy in the STZ-ICV group.
Figure 5.15. Latency in different experimental groups 
Amount of time needed for each group to solve the task in each trial. Data is
represents as the average amount of time for each group; Saline ICV n = 20 and
STZ- ICV n = 20.
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5.2.3.  MIF  inhibition  in  STZ-ICV  mice  influences  spatial  strategy
preference:
Inhibition of MIF in the brain by ISO-1 treatment (daily, IP, 20 mg/k)
had no effect on choosing the spatial strategy in STZ-ICV animals in the 12
trials (Fig.5.16). However, there was an overall significant effect obvious in
terms  of  finishing  the  task  successfully  by  employing  either  spatial  or
sampling strategies (Fig.5.17.). Vehicle-ICV treated and untreated animals do
not differ from each other,  whereas the data for STZ-ICV injected animals
seem to be noisier,  and does not  differ  from the STZ-ICV mice that  were
treated with ISO-1.
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Figure 5.16. Differences in preferred strategies by STZ-ICV 
A. and B. Percentage Stack bar chart representing different strategies used by
animals to escape the clockmaze over 12 trials (Black; futile, failure in solving
the task within 60 sec, white represents sampling or chaining strategy, where
animal finds the open exit by testing every tube and green represent Spatial
memory, when animal knows the location of the exit. Data is represents as the
mean±SEM; Veh-IP n = 20 and ISO.1-IP n = 20). Either of groups showed
improvement in solving the task in terms of using spatial strategy.
C. and D. Spatial strategy in C57BL/6 mice Veh-IP and ISO.1-IP in STZ-ICV
animal.  D. ISO.1-IP treated groups performed slightly better in using spatial
strategy (Spearman = 0.36, Y = 0.0072x + 0.3349, R2=0.752. P Value (two
tailed probability) = 0.3) in comparison to Veh-IP group (C, STZ-ICV + Vehicle
IP, Spearman = 0.201, y = 0.0096x + 0.375, R2=0.0379. P Value (two tailed
probability) =0.4), however improvement either of the groups was statistically
significant.
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There  was  no  significant  main  effect  of  ISO-1  treatment  on  the
average of latencies over 12 trials (Fig.5.18). The time needed to escape the
maze decreased in  both groups (ISO-1 treatment and Veh –IP);  however,
there was no significant difference between groups. 
Both experimental groups exhibited similar rate of errors over 12 tirals (Fig.
5.19.),  indicating  that  inhibition  of  the  MIF molecule,  did  not  affect  spatial
learning in the STZ-ICV animal in the first 12 trials.
Figure 5.17. Comparison between futile and non-futile ratio
Representation of the non-Futile trials to Futile in the last 4 trials between ISO.1-
IP (n=20) and Veh-IP (n=20) in STZ-IC C57BL/6 mice. Although ISO-1 treatment
did  not  significantly  improve  the  choosing  of  spatial  strategy,  the  general
success in solving the task improved in ISO.1-IP group significantly (unpaired
student's T test, P value = 0.019171).
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Figure 5.18. Latency over 12 trials: Veh-IP vs. ISO.1-IP
Data represents the average of latencies of each group in 12 successive trials.
Improvement was not significant between the first and the last trial in either ISO-
1 treatment (Right, n=20, Spearman = 0.36, Y = 1.4307x + 25.339, R2=0.8305,
P Value (two tailed probability) = 0.1189), or in Veh-IP (Left, n=20, Spearman
-0.201,  y  =  -1.6789x +  28.695,  R2= 0.7515,  P Value  (two  tailed  probability)
=0.397
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Figure 5.19. Clockmaze; comparison of the errors made in each group over
12 trials
A. and B.  Average number of errors made by each group over 12 trials (Errors
defined average number of  times animals tries a closed exit  to solve the task
(sampling behavior).  A. The amount of  errors made by Veh IP animals (n=20)
were generally more in comparison to ISO-1 treated group B, n=20). However no
significant  differences  were  observed  between  two  experimental  groups  (C.
plotted P value (two tailed Student T-test),  comparing the differences in errors
made between Veh-IP and ISO.1-IP)
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5.2.4. Probe test for spatial recall:
Probe trials are designed to measure long-term memory as an act of
recalling. We check the percent time spent in the target area, when the tunnel
exit is physically blocked. The test is performed after the 12 acquisition trials,
with  the  purpose  to  check  for  the  long-term  memory.  Veh-ICV  injected
animals spend most of the time in the target area and relatively less time
searching for  other  potential  exits,  differing  in  this  test  from STZ-ICV that
insist on using a sampling strategy in trying to find the exit (data not shown). 
5.2.5. Reverse learning trials: 
After the probe trial, reverse trails are performed in which the exit is
moved to the opposite location in comparison to the original place.  These
trials can help confirm the observed spatial impairments. The expectation is
for the animal to remember where the platform initially used to be in the first
trials if the memory is functional, as a result of which it will take longer for this
animal  to  find the new exit  as a result  of  confusion and a biased search
strategy. In the following trials the latency should decrease as a consequence
of having a functional memory and learning the new location for the exit. 
Veh-ICV and  untreated groups tend to spend more time at  the old  target
during the initial reversal trials, but over time they learn the new exit (Fig.5
20).  The  STZ-ICV  injected  group  relies  mostly  on  searching  strategy
(chaining),  and  the  latency  is  improved  slightly  in  this  group  over  time.
Information from the last day of the reverse trials provides evidence that the
inhibition of  the MIF was able to improve the cognition in terms of  spatial
learning, as the mice exhibit  capability in using environmental cues to find
their ways towards the exit. There is a near significant main effect of ISO-1
treatment  on cumulative  proximity  scores  in  final  reverse  trials  for  spatial
memory. As highlighted by the red box in Figure 5.20.B, the ISO-1 IP group
starts showing improvement in learning the task, indicating their capabilities in
the spatial navigation, which is as mentioned before, hippocampal dependent.
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An analysis of the latency, the time needed to escape the maze, during the
reverse  learning  trials  show  that  the  performance  of  the  animals  is  not
different between treatment groups (Fig.5.21.)
Figure 5.20.  Strategy use during reverse learning trials in the clockmaze
task 
A. and B. Bar chart representing different strategies used by animals to escape
the  clockmaze  in  reverse  trials  (Trial  12  to  24,  Data  is  represents  as  the
mean±SEM; Veh-IP n = 20 and ISO.1-IP n = 20).  A and C Animal in the Veh-IP
treatment tended to worsen over time in terms of choosing the spatial strategy to
solve the task, whereas as ISO-1 treatment group showed a trend in using spatial
memory specially at the last four trials- B, (area framed in red) and D.
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Figure  5.21.  Latency  differences  in  reverse  trials  for  STZ-ICV  injected
animals, in different treatments
Data represents the average of latencies of each group in reverse trials (12 to 24).
Latency  was  significantly  decreased  in  ISO-1  treated  group  (Left,  n=20,  IP
Spearman  =0.902,  y  =  -1.0365x  +  17.248,  R2=  0.8161,  P  Value  (two  tailed
probability) = 0.00001) and Veh-IP group (Right, n=20, Spearman =- 0.895 Y =
-1.5275x + 22.772 R2= 0.7093, P Value (two tailed probability) = 0.00001)
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Figure 5.22. Reverse Trials: comparison of the errors made between two
groups.
A. and B. Average number of errors made by each group over 12 trials (Errors
defined average number of times animals tries a closed exit to solve the task
(sampling behavior).  A. Veh IP group (n=20) had more errors in comparison to
the treatment group (B, n=20), the observation however was not supported by
statistical analysis (C. plotted P value (two tailed Student T-test), comparing the
differences in errors made between Veh-IP and ISO.1-IP)
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5.2.6.  Effects  of  neuroinflammation  on  hippocampal  cytokine  gene
expression
 In the same time frame in which spatial memory is disrupted, pro-
inflammtory  cytokines  are  elevated  in  hippocampus  of  the  STZ-ICV mice.
Vehicle-ICV animals, however, have no upregulation in expression of those
mediators.  The  mRNA  was  prepared  from  hippocampus  of  different
experimental  groups  of  mice  and  reverse-transcribed  into  cDNA for  the
purpose of investigating the presence of several inflammatory cytokines to
determine any lasting changes in immune milieu of the hippocampus. As a
first step, we looked for upregulation in GFAP and Iba1, which are well known
markers  for  astrocytic  and  microglia  cells.  We  observed  an  obvious  and
significant increase in both of these markers, meaning that ICV injection of
the  STZ  molecule,  leads  to  the  activation  of  the  glial  population  of  the
hippocampus  (Fig.5.23.).  These  cells  are  considered  responsible  for  the
ongoing  and  constant  expression  of  inflammatory  mediators  such  as
cytokines.
Figure  5.23.  Upregulation  of  glial  markers  in  transcriptional  levels  in
hippocampus of STZ-ICV C57BL/6 mice
mRNA was  isolated  from hippocampus  and  reverse  transcribed,  followed  by
performing a quantitative PCR, using Bactin as housekeeping gene. The bars
represent the mean ± SEM for 10 mice per group (10 biological replicate, each of
which having two technical replicates- **P<0.02 and ***P<0.01 (Mann-Whitney
Test).Left: Increase in Glial fibrillary acidic protein (GFAP) marker in STZ-ICV
animal, as an indicator of astrogliosis, as well as upregulation ofIba-1 (Right) the
microglial marker.
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The study was followed by testing the upregulation of different inflammatory
cytokines,  such  as  interferon- ,  interferon- ,  IL-6  and  IL-12  (  Fig.5.24.).
Except  for IFN-β,  there has been a clear upregulation in the inflammatory
cytokines in the hippocampus.
Figure 5.24. cytokine response of hippocampus in STZ-ICV model
qPCR analysis, using Beta-actin as housekeeping gene. Graphs represent the
mean ± SEM for 10 mice per group (10 biological replicate, each of which having
two technical replicates- *P<0.05, **P<0.02 and ***P<0.01 Mann-Whitney Test).
STZ-ICV lead to the significant upregulation of many Inflammatory mediators such
as  TNF-alpha  (A.), IL-6  (C.)  and  IL-12p35  (D.)  in  hippocampus  of  C57BL/6
animals. The mRNA expression levels for IFN-beta remained unaffected (B.).
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5.2.7. MIF inhibition by ISO-1 molecule does not affect activation of the
glial cells: 
Based on qPCR results, inhibition of MIF did not affect the activation
of microglia or astrocyte cells, which was reflected in the similar expression
levels of GFAP and Iba-1.  Similar  observations were made in the case of
different inflammatory cytokines. Except for some levels of down-regulation
on IL-6, no obvious down-regulation has been observed in other cytokines in
the mRNA levels (Fig.5.25).
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Figure 5.25. cytokine expression in hippocampus of STZ-ICV C57BL/6, 
under different treatments: Veh-IP vs ISO.1-IP
Reverse transcribed hippocampal mRNA was used to perform a quantitative
PCR, using Bactin as housekeeping gene. The bars represent the mean  ±
SEM for 10 mice per group (10 biological replicate, each of which having two
technical  replicates).  ISO-1  treatment  did  not  affect  the  mRNA level  glial
markers (GFAP and Iba-1) or cytokines, however a trend was seen in the
case of IL-6 and IL-12p35.
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5.3. Effects of STZ-ICV related neuroinflammation on context memory
Considering  the  potential  important  role  of  the  MIF  inhibition  for
preventing this  inflammatory-related pathology,  we  decided to test  another
hippocampal related paradigm checking for contextual fear memory in male
animals (MIF-KO, C57BL/6). 
In this section the experiments were designed to:
 Investigate the regulation of inflammatory markers in the hippocampus
of  the  MIF-KO  STZ  injected  mice  in  comparison  to  MIF-KO  Veh
injected mice and WT control mice.
 Train animals for contextual fear conditioning paradigm to associate a
conditioned  stimulus  (CS)  with  an  unconditioned  stimulus  (US),
looking for deficits in learning and memory.
 Monitor the weight change in MIF-KO mice in comparison to WT mice.
  In  order  to  investigate  the  answers  to  these  questions,  MIF-KO
animals were injected intracerebroventricularly by STZ and 4 weeks
later  were  trained  for  fear  conditioning  paradigm.  The  mice  from
previous experimental setup were also tested in the fear-conditioning
task as a source of comparison.
The cued fear conditioning was conducted over the period of four days:
1. Day 1: the animals are habituated to the experiment chamber for
10 min.
2. Day 2: animals learn to associate an unconditioned stimulus (foot
shock) with conditioned stimulus (auditory tone) over 20 min. 
 3. Day  3:  Context  memory:  animals  are  returned  to  the  same
chamber in which they were shocked and the software scores the
amount of freezing.
4. Day 4: Tone memory: the original chamber is replaced and animal
is  exposed  to  the  new  chamber  followed  by  presentation  the
conditioned stimulus (auditory tone).
In the fear-conditioning paradigm the mice learned to associate the tone with
a foot shock (Fig.5.26.). 
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The amygdala, hippocampus and sensory neocortical are the areas of the
brain that play the critical role in learning process in the fear conditioning task.
While the lesions in the hippocampal area cause problems exclusively with
contextual memory (Philips and LeDoux 1992), any lesions in amygdala will
affect both tone and contextual memory (Stephen Maren 1999).
5.3.1.  Chronic  inflammation  caused  by  STZ-ICV  in  hippocampus
disrupts contextual fear conditioning in C57BL/6 mice:
In  the  behavioral  studies  we  focused  on  the  role  of  chronic
hippocampal neuroinflammation during contextual fear conditioning. WT and
MIF-KO  mice  underwent  the  fear  conditioning  protocol  and  the  percent
freezing during each phase of the task was measured. In a pilot study, STZ-
ICV animals were compared to Veh-ICV treated mice (Fig. 5. 27.). The results
presented  here  showed  a  clear  cognitive  difference  between  STZ-ICV
injected and untreated WT animals. Vehicle injected C57BL/6 animals froze
significantly  more  than  STZ-ICV  animals.  The  tone  memory  response
(amygdala dependent) was similar in both groups.
Figure 5.26. Fear conditioning: concept
The rodent is habituated to a chamber, at this point there is nothing novel about this
particular context. On the second day a tone in displayed and during that time the
foot  shock  (unconditioned  stimulus)  is  represented  to  the  animal,  which  is  just
aversive and not painful. The animal is exposed to the tone for five times. A day
later animal is returned to the chamber. Under normal healthy brain conditions the
profound fear should be present, which is measured with freezing.
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Knowing  that  STZ-induced  inflammation  in  the  hippocampus  disrupts  the
formation of the context memory, we intended to investigate the effects of MIF
inhibition on the context memory. For this purpose, two groups of STZ-ICV
animal  were  treated  daily  with  either  ISO-1  IP or  Veh-IP as  a  source  of
control.  Figure 5. 28.A.  illustrates the behavior of these animals during the
fear conditioning itself. There are no significant differences to be observed at
this step of the experiments.
Figure 5.27. Fear conditioning STZ-ICV vs Veh-ICV
A. During the training session, STZ-ICV (n=20) and Veh-ICV (n=20)- mice received
5 light shocks pairing with a tone signal, data is represented as mean ± SEM. 
B. During the context memory task, the Veh-ICV group froze significantly more in
comparison to STZ-ICV animals, analysis of variance (one way ANOVA) followed by
unpaired  t-test  was  used  to  calculate  the  statistical  significance  (***P<0.001,
F=29.691)
C. Graphs represent the reaction of each treatment group in the tone-memory task.
Bars represent the average percentage of freezing in each group in exposure to the
tone cue ± SEM. indicates no difference between experimental groups (all p>0.05)
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As tested in the fear-conditioning chamber, we observed improvements in the
contextual  memory  in  C57BL/6  mice  after  ISO-1  treatment  (Fig.5.28.B.).
Inhibition of MIF using ISO-1, significantly increased the amount of freezing in
the animals, which indicates the improvement in contextual memory, which is
considered to be hippocampus dependent ((Philips and LeDoux 1992). The
animals exhibit no differences in response to tone memory. 
Figure 5.28. Effects of MIF inhibition on fear conditioning in C57BL/6
A. The graph illustrates the average ± SEM of freezing in ISO.1-IP (red, n=20) and
Veh-IP (blue, n=20) during the training session(a tone plus shock pairing, 0.5-mA,
repeated  5  times).  Both  groups  showed  similar  reaction  during  the  Fear
conditioning session.
B. Contextual fear conditioning in STZ-ICV C57BL/6 mice, Veh vs ISO-1 treatment:
Mice were tested for this task 24h after fear conditioning session. ISO-1 treated
animals exhibit significantly higher freezing in comparison to Veh-IP, Values are
mean ± SEM, *P<0.05 (One- way ANOVA: df=1, F=4.751, Student T test P.value =
0.033)
C.  Tone memory  task,  designed to  test  the amygdala  dependent  auditory  fear
memory,  statistical  analysis  revealed  no  significant  differences  between  two
groups.
E f f e c t s  o f  M I F  o n  c h r o n i c  n e u r o i n f l a m m a t i o n 102 
To make sure that the observation made is indeed driven by MIF deficiency,
another strain of mice were added to the project. In this step we injected MIF-
KO male mice with either STZ or vehicle intracerebroventricularly. Six weeks
after injection the animals were tested in the same fear-conditioning chamber
under the same protocol performed for C57BL/6 mice. The reaction of the
MIF-KO mice in the different treatment groups is summarized in figure 5.29.
Interestingly,  we  observed  that  the  MIF-KO  mice  at  the  baseline  acted
differently  in  comparison  to  C57BL/6  mice  (Fig.5.30.).  And  the  STZ-ICV
increased the alertness and cognitive performance in these animals in the
case of both context and tone memory.
Figure 5.29. Effects of MIF deficiency in MIF-KO mice on fear conditioning,
contextual  memory  and  tone  memory  in  STZ-ICV  mice. All  results  are
presented as a mean ± SEM. 
A.  comparison  of  hippocampus  dependent  contextual  memory  between
umanipulated MIF KO represented in yellow (n=10), and STZ-ICV group (green,
n=10). Contextual memory was improved in STZ-ICV animals (One-way ANOVA,
unpaired students T testF=12.8, P=0.01).
B. Tone-memory,  after  being  fear  conditioned  with  5  tone-shock  pairings,  the
degree of freezing in response to tone was scored,one way ANOVA revealed no
significant differences between two groups for this task.
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After making the observation about the cognition in MIF-KO animals,
we  were  interested  in  monitoring  the  behavior  of  these  animals  in  the
extinction of the fear. As mentioned before, exposure to the tone, which is
associated  with  foot-shock  during  fear  conditioning,  results  in  freezing
behavior. The degree of this freezing response depends on the level of the
anxiety and functional brain structures especially hippocampus and amygdala
when it  comes to testing the contextual memory.  This test consists of  two
trials in two successive days, where the animal is repeatedly exposed to the
conditioned  stimulus,  without  any  punishment  following.  Under  normal
circumstances, this results in a decline in response to fear. We observed a
steady decline in the fear response of both STZ-ICV and Veh-ICV animals
almost to the floor level at the end of  the second day (Fig.5.31.).  Further
studies  are  necessary for  explaining  the  exact  role  on  MIF in  this  neural
circuitry.
Figure  5.30.  Contextual  fear  conditioning in  un-manipulated C57BL/6  and
MIF-KO mice 
(n = 20 in each group) - Bar graphs show mean ± s.e.m.*P< 0.05.
The contextual memory was measured by total freezing time as the animal was
placed back inside the same chamber where the fear conditioning took place after
24 hours.
Green  bars  represent  the  un-manipulated  wild  type  in  comparison  to  the  un-
manipulated MIF-KO (yellow), Significant difference was observed between two
group.
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Figure 5.31. Fear extinction in MIF-KO animals
A. and B. graphs represent comparison of Veh-ICV MIF-KO and STZ-ICV MIF-KO in
terms of percentage of freezing on the Day one (A.) and Day two (B.) of the extinction
learning protocol. The reaction to the auditory cue over time (measured in seconds)
was recorded continuously on the camera, and is represented as average freezing for
each group in  10 sec bins in  purple  for  Veh-ICV (n=10) and yellow for  STZ-ICV
(n=10).
C. Bar graphs presentation of the average freezing response during the last three
tones of each Trial for the same experiment as described above. The freezing level
decreased in both groups in from the first to the second extinction training session.
STZ-ICV group froze significantly less than Veh-ICV group.( one way ANOVA, Day 1
F= 24.39, ***P<0.001. Day 2 F=22.838 ***P<0.001)
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5.3.2.  Inhibition  of  MIF  using  ISO-1  and  MIF  deficiency  (in  MIF-KO)
rescue the weight loss after STZ-ICV surgery: 
Throughout  the  duration  of  the  study,  the  weight  of  the  animals  were
documented  on  a  weekly  basis  to  monitor  the  changes  as  a  result  of
inflammation as well as making sure that it does not drop dramatically below
the pre-surgery weight.  The food  intake  was  also  documented on a  daily
basis. Figure 5.32. represents the graph for weigh measurement for different
groups of animals throughout the study. 
After  surgery  the  body  weight  markedly  decreased  in  STZ-ICV  C57BL/6
animals,  which was inhibited by ISO-1 treatment.  Interestingly the MIF-KO
mice were protected from weight loss.
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Figure 5.32. Spaghetti plot of weight in different groups pre and post surgery,
each line represent the weight for one individual mouse before and 6 weeks after
surgery.
C57BL/6:
A-1 the horizontal line representing the steady weight before and after the surgery
in vehicle injected mice, in comparison to  A-2 where a steep drop was observed
after  the  surgery,which  was  inhibited  by  ISO-1  treatment  (A-3: daily  dose  of
20mg/kg, IP).
MIF-KO:
B-1 represents the weight of MIF-KO animal before and 6 weeks after the surgery,
the horizontal  lines represent the steady weight  in these animals in contrast  to
STZ-ICV in wild type (A-2). B-2 represents the weight documentation in the control
group.
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7. Discussion
Sustained  inflammation  is  recognized  to  have  a  critical  role  in
development and progression of neurodegenerative diseases. 
The innate immune response in the brain is mainly regulated by microglia and
astrocytes (Hernangómez et al. 2014), these cells are the main contributors to
neuroinflammation. Under normal conditions, they are transiently activated by
a variety of triggers, including pathogens, providing inflammatory mechanisms
to defeat the pathogen. 
However  chronic  activation  of  microglia  and  astrocytes  can  instigate
inflammatory  events  leading  to  neurotoxicity  through  various  molecular
signaling pathways,  as a result  of  a toxic neuronal microenvironment.  The
release  of  various  cytokines  constitutes  the  hallmark  of  the  inflammatory
response.  Indeed,  cytokines  have  gained  increased  recognition  as  critical
factors in neuroinflammation, and consequently in neuro-degeneration, both
as biomarkers (diagnosis), as well as therapeutic targets. For instance, the
levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 are considered as
indicators of inflammation (Koleva-Georgieva et al. 2011). Recent evidence
indicates that MIF, as an early cytokine, may play a critical role in regulating
the expression and release of other inflammation mediators (Bucala 1994).
This cytokine is detected in different areas of the brain like hypothalamus,
hippocampus, and perivascular epithelial cells (Silverman et al. 2005, Bacher
et al. 1998). Elevation in MIF's expression overtime is associated with chronic
inflammation (Alexander et  al.  2012).  In our  project,  we hypothesized that
inhibition of MIF as an early released cytokine upstream of other mediators of
inflammation can down regulate the inflammation. Our in vitro data indicates a
baseline  level  of  MIF  released  by  glial  cells  under  normal,  unstimulated
conditions, as was reported before (Bacher et al. 1998). The presence of this
protein  under  normal  conditions  can  be  explained  by  the  fact  that  MIF
functions also as a hormone, or neuroendocrine mediator, in addition to the
role that it plays as a proinflammatory cytokine (Mitchell et al. 2002). MIF is
known  to  be  an  early  phase  mediator  released  as  soon  as  30  min  after
stimulation (FingerleRowson et al. 2002) and plays a critical role in regulating
expression and release of other inflammatory cytokines. 
One  major  question  that  remains  to  be  answered  is  the  role  of  MIF  in
neurons.  We  made  the  interesting  observation  that  unlike  glia  cells,  the
presence or lack of MIF was uncoupled from control of cytokine production in
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MIF-KO  and  wild  type  neurons.  This  result  provides  basis  for  future
investigations  on  which  downstream-mediators  of  STZ  are  inducing  the
cytokine expression from neurons.
Our  in  vitro data support  the hypothesis  that  MIF acts as an early phase
cytokine released both from microglia and astrocytes resulting in upregulation
and  release  of  other  inflammatory  mediators.  Inhibition  of  MIF  leads  to
attenuation  of  this  response.  Although  we  observed  attenuation  of  the
cytokine  storm  in  response  to  MIF  inhibition  in  vitro, further  investigation
(using  other  inhibitors  for  MIF,  as  well  as  using  different  molecules  to
stimulate the cells such as LPS, Aß, etc...) is required to prove causality of
inflammatory changes. Following in vitro studies, we aimed to investigate the
effects  of  acute  inflammatory  response  and  MIF  inhibition  in  the  brain.
Neuroinflammation was achieved by ICV injection of the STZ molecule into
the hippocampus. Unlike other Alzheimer's models, the glial activation and
cytokine involvement in cognitive deficits can be extensively researched in
STZ-ICV model. It has been demonstrated that acute inflammatory response
subsequent to STZ treatment is sufficient to mount a microglial and astrocytic
response along with histological changes. We observed dramatic histological
alterations in the STZ-ICV group in terms of upregulation in the glial markers
such as GFAP and Iba1 in 6 weeks after the surgery.
The in vivo  qPCR results for inflammatory mediators after ISO-1 treatments
appear to be inconclusive. On one hand we observed in preliminary in vitro
studies  that  MIF  inhibition  can  effectively  down  regulate  glial  cytokine
production.  A down regulatory trend in production of cytokines in C57BL/6
STZ-ICV animals, however it was not significant. On the other hand however,
we detected absolutely no upregulation in  any of  inflammatory markers in
MIF-KO strain after STZ-ICV, showing the importance of MIF in initiating the
inflammatory  response  and  enhancing  the  expression  levels  for  other
cytokines. 
There is a possibility that one should check the time point later than 6 weeks
after beginning the ISO-1 IP (20mg/kg) treatment to investigate whether MIF
inhibition can effectively control the local inflammation in hippocampus. Also
considering the fact that mice start to exhibit improvements in spatial learning
in later trials of clockmaze followed by a significant improvement in contextual
memory in fear conditioning task while they are still receiving the treatment,
could  point  out  to  the  fact  that  the  chosen  time  frame  was  still  early  to
investigate the effects of MIF inhibition in the brain. In a different scenario, the
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detectable level of cytokines after ISO-1 treatment can be explained by the
presence  of  D-DT  or  MIF-2,  which  might  be  upregulated  in  a  negative
feedback loop and as a result of MIF inhibition.
However, due to the presence of both MIF and D-DT mRNA at baseline levels
both  in vivo and  in vitro,  we were unable to detect any changes in mRNA
expression of either of the proteins. In order to complete inhibition of MIF and
D-DT activity, further experiments are necessary to test the effects of a co-
treatment against D-DT along with using MIF inhibitor. 
It  is  known that  excessive expression of the pro-inflammatory cytokines in
response to central or peripheral stimulation can cause behavioral pathology
and cognitive deficits. For example, it has been shown that ICV administration
of IL-1β affects learning and memory especially in contextual memory (Mencl
et  al.  2000).  Also,  IL-6  elevation  and  cognitive  dysfunction  are  positively
correlated (Maggio et al. 2006; Weaver et al. 2002). Considering the evidence
on the role of MIF in regulating pro-inflammatory cytokines, we hypothesized
the attenuation of the inflammatory mediators as a result of MIF (genetically
knock-out or chemical inhibition of the molecule) will improve the hippocampal
based behavioral dysfunction observed in STZ-ICV group. Cognitive deficits
were evident in both learning and memory of STZ-ICV group in comparison to
vehicle-injected animals. At the same time point in which cognitive impairment
were detectable, pro-inflammatory cytokines were upregulated and astrocytic
reactivity  was  increased  (upregulation  in  GFAP),  pointing  out  to  the  tight
relationship  between  neuroinflammation  in  hippocampus  and  changes  in
structural  plasticity  which  may  underlie  cognitive  dysfunction  in
neurodegenerative disorders.
In  terms  of  deploying  the  spatial  memory,  we  observed  no  differences
between untreated and vehicle-injected animals, indicating the surgery itself
has no destructive effects on hippocampus and subsequently on learning and
memory  in  these  animals.  STZ-ICV  injection  in  mice,  however,  leads  to
noticeable impairments shown by failure in either learning to solve the task
spatially or being entirely unsuccessful. Success or failure in performance of
the clockmaze task can be influenced by many factors such sex, species,
age, strain, treatment and motor skills. In our experiment, however, animals
were chosen from the same litter and sex. Our screening results suggest that
sensory and motor skills  are no factors that  might  account  for  differences
observed  in  memory  performance.  Even  at  the  training  stage  of  the
clockmaze task, there was a significant difference between the performances
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of vehicle and STZ-ICV group. This can be explained by the lack of motivation
in  the  STZ-ICV  animals,  due  to  the  constant  presence  of  inflammatory
mediators  in  CNS,  which  may cause  sickness  behavior  and  difficulties  in
habituating  to  a  new  stressful  environment.  This  study  showed  the  MIF
inhibition improved reference memory performance in the final trials in STZ-
ICV animal group, as compared to agematched STZ-ICV groups, but had no
significant effects on cognitive flexibility. However, some evidence suggests
limited beneficial role of MIF inhibition in cognition, which was observed in the
late trials, Thus further work is necessary in this model to determine the exact
anti-inflammatory  therapeutic  potential  in  inhibition  of  MIF.  Our  chosen
application  method  (daily  IP)  may not  be  the  most  appropriate  option  for
delivering the drug to the brain of the animals. It has been previously shown
that ISO-1 is capable of crossing the blood brain barrier, yet it doesn’t mean
that all the IP injected substance, finds its way into the CNS. Insufficient dose
to elicit the protective effects may be an explanation why the expected effect
was not observed. Optionally, one might suggest that intravenous injections
or  intracerebroventricular  treatment  with  ISO-1  represent  better  routes  of
injection.  Both  routes  of  administration  are  not  considered  easy  choices.
Intravenous (IV) applications are considered difficult  in murine models and
ICV interventions are accompanied by many side effects apart  from being
challenging and tiring for the health status of the animal itself. Increasing daily
treatment  sessions  maybe  another  option  in  order  to  increase  the
concentration of ISO-1 in the CNS and as a result of that increased inhibition
of MIF molecule. Alternatively, we can continue with ISO-1 IP daily regimen
and assess the re-learning of the task in these mice after a longer period of
time,  to  control  whether  there  is  any  sign  in  recovery  in  spatial  memory.
Optionally one may try other inhibitors for the MIF molecule. 
Upregulation of the cytokine was used as an indicator for presence of chronic
neuroinflammation  in  the  brain,  however  we  detected  no  expression  for
different cytokines in the hippocampus of the MIF-KO animals. The fact that
STZ injection in these animals did not elevate those cytokines in contrast to
WT animals, strongly suggests that MIF plays a key role in this inflammatory
response.
In tone memory task, the mice learn to associate the one (CS) and the foot-
shock  (US),  the  task  is  mainly  controlled  by  amygdala.  Lack  of  cognitive
impairments in the case of tone memory task in fear conditioning indicates to
the fact that the observed hippocampal dependent cognitive deficits are not
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as a result  of  systemic changes,  but  occur following local changes (either
histological or inflammatory) in hippocampus area. However due to the small
size  of  the  mouse  brain,  it  was  not  possible  to  obtain  separate  mRNA
samples  from  amygdala  to  check  the  levels  for  expression  of  different
cytokines. Systemic neuroinflammation models can be used in order to test
whether MIF inhibition can affect amygdala associated behaviors or not. In
contrast to tone memory different treatment groups of mice exhibit significant
differences in amount of freezing time in hippocamapal dependent contextual
memory.  These  results  showed  a  deficit  in  contextual  memory,  possibly
related  to  neuroinflammation  or  neurodegeneration  caused  by  STZ in  the
hippocampal  area,  which was  even more confirmed by having the similar
response  in  the  tone  memory,  which  is  amygdala  dependent.  We  also
observed a significant protective effect followed by ISO-1 IP injection, which
was reflected in increased total time of freezing in these mice in comparison
to Veh-IP injected STZ-ICV mice. ISO-1 binds to tautomerase active site in
the MIF molecule, resulting in inhibition of the cytokine activity of MIF. These
findings are congruent with existing literature, which shows that inhibition of
MIF leads to  down-regulation  of  the  cytokines  (Al-Abed et  al.  2005).  It  is
therefore reasonable to assume that deficits in hippocampal based cognition
can be targeted through attenuation of cytokine production. For this purpose
MIF seems be a proper target. Our data provides evidence that due to lack of
MIF  in  the  MIF-KO  mouse  strain,  these  animals  were  protected  against
upregulation of many cytokines after STZ stimulation. 
There is a general difference in the overall behavior of the MIF-KO mice and
WT animals, which can be interpreted as sickness behavior resulting from the
lack of MIF in these MIF-KO mice. It has been previously shown that the MIF-
KO mice exhibit depressive like behavior (Bay-Richter et al. 2015). This might
as well indicate the role of MIF in inflammatory processes that are present in
psychotic disorders, also raising question whether there shared mechanism
between sickness like or depressive behavior and dementia exist. It has been
suggested  that  brain  inflammation  around  hippocampal  NMDA receptors
(NMDA-R1)  can  lead  to  neurodegeneration  in  the  glutamatergic  neurons
expressing these receptors, which is associated with behavioral deficits (Rosi
et  al.  2004).  Our  results  support  this  hypothesis  by  showing  that  the
contextual  memory  can  be  rescued  by  down  regulating  the  inflammation,
however  one  of  the  limitations  of  this  study  is  the  lack  of  data  on  the
expression  of  the  NMDA  receptors  in  response  to  STZ  and  also  after
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inhibition of MIF. 
In summary, these data delivered further insight into the possible role of MIF
as  an  early  cytokine  in  neuroinflammatory-dependent  cognitive  deficits  in
neurodegenerative disorders by showing that MIF inhibition might provide a
basis  for  new  therapeutic  approaches.  However  further  experiments  are
necessary to improve the understanding of MIF's role in the pathway of glial
activation  during  the  neuroinflammation.  One  other  possible  mechanism
through  which  STZ  may  induce  cognitive  impairments  is  via  excessive
accumulation of NO, which leads to activating the activator protein-1 pathway
(AP-1,  Angel  and  Karin  1991),  sustained  activation  of  AP-1  induces
upregulation of iNOS (Mendes. AF, et al. 2003). at the later time points after
the  surgery  the  NO  production  can  be  induces  by  presence  of  certain
inflammatory components such as TNFα (Eberhardt et al. 1996). 
In  parallel  to  cognition  studies,  the  weight  of  the  animals  was  also
documented regularly.  Interestingly,  our  results  indicate that  both inhibition
and lack of MIF molecule, rescues the weight loss which is typical after STZ-
ICV interventions. The weight drop in the first  week by all  animals can be
explained by the fact that animals may avoid the food as a result of the pain in
the head area as a result of surgery. After recovery from the surgical shock
however, the STZ-ICV C57BL/6 mice continue losing weight. This anorectic
effect may occur as a consequence of changes in the metabolic rate as a
result  of  activation  of  the  inflammatory  pathways  in  the  hippocampus.
Conditions associated with chronic inflammation, such as sepsis and chronic
viral infections like HIV) in CNS are shown to be linked to insulin resistance
development  (Gregor,  Hotamisligil  2011).  Increase  in  the  levels  of
inflammatory cytokines such as IL-6 and TNF a can influence the weight of
the animals (Mohamed-Ali et al. 1997). Both IL-6 and TNFa are capable of
inhibiting insulin signaling directly. Several serine kinases become activated
as  a  result  of  upregulation  of  these  cytokines,  which  affect  the
phosphorylation  of  IRS-1,  a  critical  member  for  insulin  signaling  pathway.
Thus their upregulation will result in losing sensitivity to the insulin or insulin
resistance (Gual et al. 2005). It has also been shown that taste aversion can
be induced in the rats by injection of IL-1 (Tazi et al. 1988), which might lead
to changes in the appetite and thus suppressing the food intake. 
Our experimental  evidence suggests that  lack of  MIF molecule as well  as
inhibiting its cytokine activity by ISO-1 molecule protects the mice from severe
weight loss. 
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The purpose of the current study was to investigate the effect of MIF inhibition
on  neuroinflammation  induced  by  ICV  administration  of  STZ  on  cytokine
production as well as cognition. Our Initial investigation results have shown
that neuroinflammation is playing a pivotal role in causing cognitive deficits as
well as improvement in cognition as a results of MIF inhibition. MIF inhibition
can affect the inflammatory milieu and cognition, however the effect does not
seem to be immediate, and can be first detected after 6 weeks of treatment in
the animal (considering the delayed improvement of mice in clockmaze and
overall  better  performance in  second context-memory task while  on ISO-1
regimen) Neuroinflammation driven cognitive impairment happens as a result
of  complex  interactions  between  different  arms  of  immune  and  nervous
system. It should be further investigated whether the observed improvements
are due to cytokine down regulation or as a results of MIF effects on synaptic
plasticity and neurogenesis processes.
Using anti-inflammatory strategies such as MIF inhibition is a potential option
to improve cognition in patients suffering from neurodegenerative diseases
with a prevalent neuroinflammation. Continued research on MIF inhibition as
therapeutic target is necessary to provide further insights in the role of this
early cytokine in both neuroinflammation and cognition. 
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